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Abstract 
Several clinical studies have demonstrated that intrauterine growth restriction (IUGR) 
offspring, faced with a nutritional mismatch postpartum, have an increased risk of developing 
the metabolic syndrome. The maternal protein restriction (MPR) rat model has been 
extensively studied to investigate the adverse effects of a nutritional mismatch in postnatal 
life of IUGR offspring. Previous studies have demonstrated that MPR leads to impaired 
function of the liver, an important metabolic organ for lipid and glucose homeostasis along 
with drug catabolism. However the underlying mechanisms which predispose these offspring 
to the metabolic syndrome remain elusive. In the following studies, low protein diet during 
pregnancy and lactation led to IUGR offspring with decreased liver to body weight ratios, 
followed by increased circulating and hepatic cholesterol levels in both sexes at day 21 and 
exclusively in the male offspring at day 130. These long-term increases in cholesterol levels 
mirrored decreases in cholesterol 7α-hydroxylase (Cyp7a1), a rate-limiting enzyme that 
catabolizes cholesterol to bile acids. This was due, in part, to diminished acetylation and 
enhanced methylation of histone H3 [K9,14], markers of chromatin silencing, at the promoter 
region of Cyp7a1. It was later demonstrated that these IUGR offspring exhibited increased 
molecular markers of hepatic endoplasmic reticulum (ER) stress and insulin resistance 
exclusively when they were faced with a nutritional mismatch in postnatal life. Finally, as 
cytochrome p450 (Cyp) dependent enzymes reside in the ER of the liver and are the primary 
enzymes involved in Phase 1 of drug metabolism, it was relevant to determine whether MPR 
lead to long-term alteration in their ability to metabolize drugs (e.g. statins for 
hypercholesterolemia). MPR offspring were shown to have an increase in enzymatic activity 
of the major drug metabolizing enzymes Cyp3a and Cyp2c. This was postulated to be due, in 
part, to transcriptional induction by constitutive androstane receptor. Collectively, these 
findings suggest that stable promoter-specific changes to post-translational histone 
modifications and elevated ER stress in the liver, are key molecular mechanisms whereby 
IUGR offspring receiving a nutritional mismatch in postnatal life develop high cholesterol 
and insulin resistance. Moreover, it can be postulated that these offspring require augmented 
doses of drugs in order to effectively alleviate these symptoms.  This new knowledge would 
serve useful in the development of both prevention and management strategies to reduce the 
debilitating impact of metabolic diseases in low birth weight babies. 
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A portion of this Introduction has been reproduced (adapted) with permission from: Sohi G, Revesz A, 
Hardy DB (2011) Permanent implications of intrauterine growth restriction on cholesterol homeostasis. 
Semin Reprod Med 29(3): 246-56. 
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1.1 Cardiovascular Disease  
While significant advances in medicine have been made over the past 50 years to 
improve overall health, cardiovascular disease (CVD) still remains the leading cause of 
premature death worldwide. Without dispute, the risk of developing cardiovascular 
disease increases in individuals diagnosed with the metabolic syndrome. For example, a 
1998 prospective Québec cardiovascular study has demonstrated that adults with the 
metabolic syndrome have a ~18-fold risk of developing CVD compared to adults who do 
not exhibit this syndrome
1
. Moreover, the incidence of metabolic syndrome in Canada is 
reaching epidemic proportions, with one in three Canadian family practice patients 
between 40 and 60 years of age falling under this criteria
2
. The World Health 
Organization (WHO) has identified hypercholesterolemia and insulin resistance, in 
addition to obesity and hypertension as one of the major symptoms characterizing the 
metabolic syndrome
3, 4
. Specifically, WHO criteria for metabolic syndrome include 
insulin resistance as identified by type 2 diabetes or impaired fasting glucose and/or 
tolerance, alongside any two of the following: high blood pressure (≥140 mm Hg systolic 
or ≥90 mm Hg diastolic), high density lipoprotein (HDL) cholesterol <0.9 mmol/L in 
men or <1.0 mmol/L in women, plasma triglycerides ≥1.7 mmol/L, BMI >30 kg/m2 or 
urinary albumin excretion rate ≥20 μg/min5. While the criteria for metabolic syndrome 
only encompasses low levels of HDL plasma levels, hypercholesterolemia could be due 
to high levels of low density lipoprotein (LDL) or HDL levels depending on whether we 
are detecting it in the plasma levels of rodents (e.g. mice or rats) or humans. This is 
because humans predominantly carry cholesterol in the form of LDL while rodents 
predominantly carry cholesterol in the form of HDL
6
. Therefore, in this thesis 
“hypercholesterolemia” is with reference total circulating cholesterol levels. 
1.2 Impact of Hypercholesterolemia and Impaired Glucose 
Tolerance on Cardiovascular Disease 
Maintaining normal cholesterol levels and glucose homeostasis is critical for reducing the 
risk of developing CVDs. For example, a meta-analysis prospective study, using data 
from 58 clinical trials as well as nine cohort studies, indicates that in patients with 
3 
 
 
cardiovascular disease, a 1.8 mM reduction in low density lipoprotein (LDL) cholesterol 
by statins from pretreatment concentrations of 4.8 mM resulted in a 17% reduction in 
stroke and a 60% reduction in the risk of ischemic heart disease
7
. While statin therapies 
are considered safe and effective, incidences of statin induced skeletal muscle damage 
(i.e. rhabdomyolysis) and hepatitis associated liver failure exist in some patients
5
. 
Similarly, individuals with impaired glucose tolerance have been estimated to have twice 
the risk for developing cardiovascular disease
8
. Therefore, targeted treatment of 
hyperglycemia, notably by metformin, is considered to be an effective strategy in 
preventing cardiovascular disease in diabetic patients
9, 10
. However, many individuals 
with impaired glucose intolerance and high cholesterol display no symptoms for many 
years, resulting in premature mortality due to a failure to receive timely diagnosis and 
treatment
11-13
. Therefore, despite current therapeutic modalities which are aimed to 
reduce the incidence of the metabolic syndrome through lifestyle modifications (i.e. 
changes in diet and physical activity) and/or pharmacological interventions, CVD still 
remains the leading cause of mortality in North America. As a consequence, this places 
an enormous human and economic burden on society, where 1 in every 2.9 deaths in the 
United States is due to CVD
14-17
. In order to effectively alleviate the burden of this 
pandemic proactive development of strategies which focus on disease prevention prior to 
the manifestation of the adverse symptoms are warranted. 
1.3 Developmental Origins of Adult Disease  
The ‘fetal origins’ or ‘Barker’ hypothesis suggests that adverse maternal events that lead 
to impaired fetal and neonatal growth results in offspring that are at a higher risk of 
developing chronic diseases in later life (Figure 1.1)
18-20
. Epidemiological evidence 
strongly indicates that adverse events in utero (i.e. maternal hypoxia, undernutrition, 
infection, stress) can permanently alter physiological processes leading to the metabolic 
syndrome
21, 22
. As a result, the last two decades have witnessed an increase in clinical and 
animal studies focused on understanding the role of the fetal environment in the long-
term regulation or ‘programming’ of metabolic functions. Moreover, these studies have 
also sought to elucidate the molecular mechanisms involved in the etiology of these 
metabolic diseases in adult life. In understanding the role of the perinatal and/or postnatal 
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environment on long-term health, therapeutic intervention strategies can be targeted to 
prevent the onset of the metabolic syndrome. 
Despite our best efforts, the rates of preterm and low birth weight pregnancies have 
increased over the previous two decades in Canada and the United States 
(www.marchofdimes.com/peristats)
23
. Given these trends, it is noteworthy that a majority 
of metabolic syndrome related diseases have been linked to adverse events in utero
21, 24, 
25
. While low birth weight is the most common indicator used in clinical studies to 
correlate impaired fetal development and adverse outcomes in adulthood, the nature of 
the growth restriction (e.g. asymmetrical vs symmetrical IUGR) may alter this 
relationship. For instance, symmetric growth restriction refers to when the entire body is 
proportionally small. As a consequence, expert medical evaluation is required to 
distinguish whether the symmetric IUGR is due to pathological or normal development 
process
26
. This evaluation is important before a correlation between symmetric IUGR and 
adverse postnatal consequences can be investigated. On the contrary, placental 
insufficiency predominantly underlies most cases of asymmetric growth restriction, 
where the offspring has a normal head dimension but reduced abdominal circumference 
and limb size
26
. It is now well established that asymmetric IUGR has a strong correlation 
with increased risk of adverse outcomes in adult life. Lastly, aside from a careful 
consideration of the type of IUGR as a predictive indicator of these outcomes in 
adulthood, confounding factors also need to be accounted for. Most notably, these 
include influence of maternal socioeconomic status
27
, preexisting maternal CVD risk 
factors
28
, maternal smoking/high blood pressure
29, 30
 and maternal BMI
31-33
 on birth 
weight and adult diseases. 
1.4 Thrifty Phenotype Hypothesis  
The postnatal environment can also influence the correlation between IUGR and CVD. 
For instance adverse events during development induce fetal adaptations that allow for 
optimal survival in a similar predictive environment in postnatal life. However, the 
“thrifty phenotype” hypothesis suggests that these adaptations can become maladaptive if 
there is a ‘mismatch’ to the predictive environment34, 35. Clinically, low birth weight 
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offspring that underwent rapid postnatal catch-up growth due to mismatch in their 
postnatal environment (i.e. infant formula diets, overnutrition) displayed earlier 
indications of glucose intolerance, insulin resistance, dyslipidemia, obesity and higher 
death rates due to CVD (Figure 1.1)
36-40
.  In addition, appropriate neonatal growth rates 
(i.e. due to breastfeeding) had a lower risk of hypercholesterolemia
42
, type 2 diabetes
43
, 
obesity
44
 and CVDs
45
. 
1.5 Clinical Perspective: Developmental Origins of 
Hypercholesterolemia and Impaired Glucose Tolerance 
To date, numerous studies have demonstrated a strong inverse association between birth 
weight and metabolic risk factors associated with CVD (Figure 1.1)
46-49
. With respect to 
cholesterol, the first study to observe a link between development and subsequent 
dyslipidemia was conducted by Forsdahl in 1978
50
. This study detected a significant 
positive correlation between poor living conditions in early childhood (based on the 
infant mortality rate) with higher cholesterol in men and women aged 35-49 years from 
within the same geographical area. In addition, a cohort of this study was also found to 
have an increased risk of coronary heart disease
51
. Similarly, Amendt in 1976 observed 
adolescents born to diabetic mothers displayed early symptoms of diabetes including 
impaired glucose intolerance
52
. Since these initial observations, the correlation of fetal 
growth to elevated cholesterol levels and glucose intolerance in adult life was popularized 
by the work of Barker and colleagues
53, 54
. Moreover, Barker also demonstrated that a 
positive correlation existed between birth weight and increased risk of death from 
ischemic heart disease
46
. Many of the initial clinical data suggest strong support for low 
birth weight being linked to an atherogenic lipid profile and type 2 diabetes in adult life 
45, 55-57
. However, some studies have indicated some inconsistencies with respect to this 
profile and ischemic heart disease
58, 59
, despite a strong correlation with type 2 diabetes
60
. 
Some have argued that impaired fetal growth, as indicated by low birth weight, does not 
necessarily affect adult cholesterol levels enough to have any clinically significant effect 
in developing CVD
31
. These authors further suggested that previous studies 
demonstrating strong inverse associations between birth weight and postnatal cholesterol 
levels were influenced by a publication bias resulting from inappropriate adjustment for 
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current weight and other confounding factors
31
. In addition, they argue that 
socioeconomic status has been demonstrated to have a greater impact on adult lipid levels 
when compared to birth weight
61
. 
In light of these arguments, it is still important not to underestimate the role of fetal 
development in the programming of adult cholesterol metabolism, type 2 diabetes and 
ischemic heart disease. First and foremost, a majority of studies use birth weight as an 
indicator of restricted fetal growth, although this may not be the best marker of fetal 
development. Secondly, while different in utero conditions (i.e. undernutrition, hypoxia, 
excess glucocorticoids) can result in low birth weight, it does not necessarily mean that 
all of these conditions impair the development of organs (i.e. liver, small intestine) in a 
similar manner that is critical to cholesterol homeostasis. Interestingly, as the liver is a 
major site of cholesterol regulation, it has been demonstrated that abdominal 
circumference at birth, which provides an indirect measure of liver growth, has a stronger 
correlation with adult dyslipidemia than birth weight
55
. The next generation of follow up 
studies need to better incorporate in utero biomarkers for the earlier detection of 
abnormal liver development. Thirdly, care must be taken while drawing conclusions from 
meta analysis studies investigating links between birth weight and cholesterol levels later 
in life, as many studies used in the meta analysis examine cholesterol levels at different 
postnatal timepoints
31, 58
. This can influence the strength of the correlation because as one 
ages, adaptive responses to maintain cholesterol levels early in life may become 
maladaptive. Finally, these meta-analysis include studies which have variations with 
respect to gender, genetic makeup or postnatal environment, all of which may also further 
diminish this correlation
62
. Since twins experience a relatively similar environment 
during fetal and postnatal development, clinical studies involving twins would be less 
prone to the effects of the previously discussed factors. In addition, monozygotic twins 
would be particularly useful, as their genetic variability would be minimal. However, 
there has been an issue concerning the use of twins in linking birth weight to metabolic 
disease given their low statistical size
63, 64
. Future clinical studies should address some of 
the highlighted shortcomings from earlier studies in order to better understand the 
implications of impaired development on long-term cholesterol regulation and ischemic 
heart disease. Given the time involved for these follow-up studies, animal models are 
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beneficial in aiding our understanding of the molecular mechanisms involved in the 
developmental origins of long-term cholesterol and glucose homeostasis.  
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Figure 1.1: Developmental origins of adult disease schematic. Several in utero insults 
leading to low birth weight offspring can increase the risk of metabolic syndrome in 
adulthood and subsequent risk of cardiovascular disease. This risk is further increased if 
the low birth weight offspring undergo rapid postnatal catch-up growth, leading to a 
thrifty phenotype. 
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1.6 Animal Models in the Developmental Origins of 
Hypercholesterolemia and Impaired Glucose Tolerance 
Even before the formulation of the Barker’s hypothesis, animal models have successfully 
demonstrated that impaired fetal development compromises the ability of the offspring in 
regulating cholesterol or glucose in adult life. For example, premature weaning in rats 
was demonstrated to result in increased serum cholesterol levels and an inability to 
respond to a cholesterol challenge in the adult offspring
65, 66
. In addition, studies in 
guinea pigs have indicated that premature weaning leads to cholesterol dysregulation at 
postnatal day 10 and day 45
67
. This was attributed to decreases in cholesterol 7α-
hydroxylase (Cyp7a1) activity, the rate limiting enzyme involved with the conversion of 
cholesterol to bile acids. Furthermore, sows with pharmacological induced gestational 
diabetes have been associated with offspring that exhibit impaired insulin response and 
glucose intolerance in neonatal life
68
. While these studies suggest that perturbations in 
fetal and neonatal life can have short-term consequences on cholesterol and glucose 
homeostasis, there are limited studies that address the effects of in utero insults on long-
term programming of glucose and cholesterol homeostasis. In addition, the long-term 
impact of factors that contribute to the “Thrifty Phenotype” in these offspring has not 
been elucidated. The most notable intrauterine insults associated with impaired fetal 
development are decreases in nutrients and oxygen delivery to the fetus. Therefore, it is 
important to delineate the contributions of both nutrition and hypoxia to long-term 
metabolic diseases.  
1.6.1 Effects of Hypoxia on Long-term Cholesterol and Glucose 
Homeostasis 
Using the rat as a model, maternal hypoxia during pregnancy has been demonstrated to 
lead to IUGR, impaired liver development, cardiac remodeling, diastolic dysfunction and 
increased sensitivity to ischemia in adulthood
69, 70
. While this model is an excellent 
model to study the fetal origins of CVD, the effect of maternal hypoxia on components of 
the metabolic syndrome preceding CVD (e.g. hypercholesterolemia) are less understood. 
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Recent evidence suggests that maternal hypoxia derived offspring have impaired ability 
to regulate cholesterol leading to hypercholesterolemia when administered a high-fat 
dietary challenge at 10 months of age
71
. Moreover, maternal hypoxia during pregnancy 
led to increased risk of developing CVD, as there were indications of early pathological 
appearances of atherosclerosis in adult offspring
71
. Surgical ligation of the uterine artery 
(gestational day 19-21) in rats is a commonly used method to induce IUGR by reducing 
uteroplacental blood flow. This method has been previously demonstrated to decrease β-
cell mass and impair glucose tolerance by 7 weeks of age
72
. At 9 weeks of age the IUGR 
offspring display hyperlipidemia and become insulin resistant
73
. Apart from reducing 
oxygen supply, decreasing blood flow by uterine ligation also reduces the transfer of 
amino acids, glucose and insulin. Therefore, it becomes difficult to delineate the direct 
effect of hypoxia on long-term disease risks in this experimental model of hypoxia. 
Placing rats in hypoxic chambers during gestation is usually the alternate approach 
undertaken to circumvent this issue
69, 70
. Typically, rats are placed under an enclosed 
hypoxic chamber with an oxygen concentration of 10% during the last 6 days of 
gestation
69, 70, 74
. Interestingly, prenatal hypoxia independent of undernutrition has been 
demonstrated to promote molecular markers of insulin resistance and increased cardiac 
susceptibility to ischemia injury
69, 74
.  However, recent work in our laboratory has 
demonstrated that this maternal hypoxia model leads to decreases in circulating glucose, 
but no change in cholesterol in 12 month offspring
75
. Additional work is required to 
elucidate the molecular mechanisms behind this observation.  
1.6.2 Maternal Iron Restriction in Rodents on Long-term 
Cholesterol and Glucose Homeostasis  
Given that ~50% of pregnant women are iron deficient and that maternal anemia is linked 
to abnormalities in birth weight
76
, animal models of iron restriction have been utilized to 
explore the link between impaired fetal development and long-term diseases. In rats, 
maternal iron restriction has been demonstrated to lead to decreases in fetal weight and 
plasma cholesterol levels, but an increase in fetal hepatic cholesterol
77
. In addition, this 
corresponded with reduced expression of fetal hepatic expression of key cholesterol 
catabolism (i.e. Cyp7a1) and triglyceride synthesis (i.e. Srebp1-c) genes
77
. Consequently, 
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there was a reduction in the hepatic expression of Srebp1-c downstream transcriptional 
target genes Fatty acid synthase (Fas) and Acetyl-coenzyme A carboxylase- (Acc)79. 
Interestingly, maternal iron restriction did not alter plasma cholesterol levels and actually 
improved glucose tolerance in the offspring by three months
78
. This suggests that iron 
restriction in utero has short-term effects on fetal liver function which may be corrected 
with restoration of maternal iron postpartum. This recovery in function is likely to be due 
to the highly plastic nature of the rat liver during the first three weeks of neonatal life
79
. 
However, it still remains possible that maternal iron restriction may alter hepatic 
cholesterol and glucose regulation long-term (>3 months). In order to accurately 
extrapolate these findings to assess the impact of maternal iron deficiency on long-term 
liver function in humans, an iron deficient diet should continue to be administered for the 
first three weeks of postnatal life in these rat offspring, since in rodents liver 
differentiation develops late in gestation with a large portion of it occurring in postnatal 
life. In contrast, liver differentiation in humans already occurs by early to mid-
gestation
80. Therefore, at birth the rat liver is ‘less’ mature and has greater plasticity than 
the human liver. This makes the rat liver more susceptible to further insult or recovery 
during early neonatal life 
1.6.3 Effects of Low Protein Diet on Long-term Cholesterol and 
Glucose Homeostasis 
While iron restriction in pregnancy has been demonstrated to lead to IUGR and elevated 
fetal cholesterol levels
77
, the maternal protein restriction (MPR) rat model is one of the 
most widely used animal models to investigate the correlation between IUGR and adult 
diseases. Since amino acids play a critical role in fetal growth
81
, this MPR model is a 
relevant model to study the fetal origins of adult diseases. Furthermore, as placental 
insufficiency in humans can produce protein deficiency in the fetus
82
, this MPR model 
shares features in common with IUGR, which represents 8% of newborns
19, 20
. Studies of 
Wistar rats have demonstrated that a MPR diet (8% protein vs 20% protein control) 
during gestation and lactation results in decreased birth weight (asymmetrical IUGR
83
), 
and permanently reprograms the functions of various organs including the pancreas
84-86
, 
muscle
87
, adipose tissue
88
 and liver
89-92
. In the liver, reduced maternal dietary protein is 
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associated with alterations in hepatic glucose output, decreased glucagon receptor and 
glucokinase expression, along with increases in hepatic lobular volume
90
. As a result of 
MPR on the function of these organs, the offspring exhibit increased visceral fat
88
, 
symptoms of type 2 diabetes
93, 94
, and hypertension
95, 96
 in adulthood. Given that these 
symptoms characterize the metabolic syndrome
97
 which substantially increases the risk 
for CVD
1
, this MPR model is very useful to study the fetal programming of CVD. 
However, the role of MPR on circulating cholesterol, another important clinical risk 
factor characterizing the metabolic syndrome
97
, remains elusive. 
There is growing evidence that individual amino acids may be as important as the overall 
levels of macronutrients in determining size at birth and postnatal disease risk. For 
example, supplementing a MPR diet with glycine alone can prevent postnatal 
hypertension
98
. Others have demonstrated that taurine supplementation to the MPR diet 
during pregnancy and lactation restores islet proliferation and pancreatic 
vascularization
99, 100
. Future research on the role of micronutrients during development on 
the risk of postnatal diseases is anticipated with great interest. For a review on the role of 
macronutrients in the developmental origins of health and disease, please see a review 
article previously published by our laboratory
101
.  
Collectively, animal models of IUGR provide further support for the hypothesis that 
impaired development due to various maternal deficiencies can lead to impaired glucose 
and cholesterol homeostasis in adulthood
77, 85, 102-104
. These deficiencies in humans and 
animals can include hypoxia
71
, diminished protein
105
, caloric restriction
106
, excess 
glucocoritcoids
107, 108
, infections
109
 or deficiencies in the microenvironment including 
specific amino acids, vitamins and minerals
78, 98, 110-112
. Although the correlation between 
impaired development and the risk of developing chronic disease in adult life is 
undoubtedly strong, the molecular mechanisms behind programming of 
pathophysiological processes are only beginning to be elucidated.  
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1.7 Molecular Mechanisms Underlying the Early Programming of 
Metabolic Syndrome 
Regardless of the type of in utero insult, animal models comprehensively demonstrate 
that the long-term regulation of cholesterol and glucose homeostasis is permanently 
altered in IUGR offspring. However, the molecular mechanisms underlying these events 
are only beginning to be uncovered.  
1.7.1 Transcriptional Mechanisms Underlying the Early 
Programming of Metabolic Syndrome 
Without question, understanding the role of transcription factors in this process will 
provide us with specific drug targets for the prenatal and postnatal prevention of these 
adult diseases. Nuclear receptors represent the largest family of transcription factors 
found in metazoans, binding to steroid hormones, fat-soluble vitamins, along with 
oxysterols and bile acids from the diet
113
. Although the roles of many nuclear receptors 
are well defined, very little is known about their function in fetal programming. As 
mentioned previously, a subset of nuclear hormone receptors, namely the Liver X 
Receptors (LXRα and LXR), are important mediators of cholesterol and glucose 
homeostasis in the adult by serving as important transcription factors
113, 114
. Both 
receptors share 77% homology and heterodimerize with the Retinoid X Receptor (RXR) 
to activate a wide variety of downstream target genes important for glucose synthesis and 
uptake, and cholesterol metabolism and efflux
113, 114
. The LXR/RXR heterodimer can be 
activated by both RXR ligands (i.e. retinoids) and LXR ligands (i.e. oxysterols)
113
. Upon 
ligand activation there is a recruitment of coregulators at the LXRE site of LXR target 
genes
115
. The LXRα isoform is highly expressed in the liver but is also abundant in 
macrophages, the intestine, muscle, adipose and kidney, while LXRβ is ubiquitously 
expressed
113
. One of the main functions for LXRs is activating the expression of 
cholesterol 7a-hydroxylase (Cyp7a1), the rate-limiting enzyme for the conversion of 
cholesterol to bile acids. Studies where adult mice were fed a diet 100 times greater than 
their normal daily cholesterol intake found that they did not form atherosclerotic 
lesions
116
. This was demonstrated to be due to an LXRα-mediated increase in the 
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expression of Cyp7a1
116
. However, mice deficient in LXRa lose the capacity to 
catabolize dietary cholesterol, via decreases in the expression of Cyp7a1, along with 
impairments in sterol and fatty acid synthesis
117
. These studies implicate the important 
role of LXR in cholesterol homeostasis. The LXR knockout mouse does not exhibit 
any alterations in bile acid metabolism
118
, however mice deficient in both LXR and 
LXR exhibit a more severe phenotype than LXR null mice alone with respect to 
cholesterol dysregulation
119
. In addition to promoting cholesterol catabolism (i.e. 
Cyp7a1), LXR and LXR regulate transcription of a number of other target genes 
involved with cholesterol homeostasis, including efflux (ATP-binding cassette 
transporters ABCA1, ABCG5 and ABCG8) and high density lipoprotein (HDL)-mediated 
reverse transport (apoE, PLTP, CETP)
115
. Mutations in several of these LXR target genes 
have major effects on circulating cholesterol concentrations and upon cardiovascular 
disease
120
. For instance, humans lacking functional ABCA1 exhibit lower circulating 
HDL, increased arterial wall thickness, and a 6-fold increased risk for cardiovascular 
disease
121
. In addition, humans or mice deficient in apoE have elevated plasma 
cholesterol (LDL), triglycerides, and cardiovascular risk
122, 123
. More recently, the role of 
LXR as an important regulator of glucose homeostasis has been established
124
. 
Specifically, LXR has been found to repress critical genes involved with glucose 
production, including glucose-6-phosphatase (G6Pase), phosphoenolpyruvate 
carboxykinase (Pepck) and 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1), and 
increased expression of genes involved with glucose uptake, including glucose 
transporter 1 and 2
125-127
. G6Pase and Pepck are genes involved with gluconeogenesis, 
while 11β-HSD1 increases glucose production by converting inactive corticosteroids to 
their active form (Figure 1.2). 
Given that LXR plays a role in both cholesterol113 and glucose114 homeostasis, it is an 
attractive candidate for elucidating the molecular mechanisms underlying the etiology of 
the metabolic syndrome. To date, few studies have demonstrated links between nutrition, 
LXRs and liver function. Our laboratory has recently demonstrated that maternal hypoxia 
during pregnancy decreases the expression of hepatic G6Pase in adult offspring due to 
repressive changes at the DR-4 LXRE region (-258 to -169) of the rat G6Pase 
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promoter
75
. Both iron restriction and maternal protein restriction have been demonstrated 
to lead to decreased fetal LXR77, 128, but less is known about the long-term effects in 
postnatal life. Further work on the role of LXR, RXR, and other lipid-sensing nuclear 
receptors are warranted to understand the transcriptional mechanisms involved in 
cholesterol dysregulation and impaired glucose tolerance. 
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Figure 1.2: Schematic Diagram of LXR and some of its main downstream target genes 
involved with fatty acid synthesis, cholesterol homeostasis and glucose homeostasis. + = 
positively regulate, - = negatively regulate. 
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1.7.2 Epigenetic Mechanisms Underlying the Early Programming 
of Metabolic Syndrome 
Epigenetics is an important mechanism in regulating the expression patterns of genes in a 
site and tissue specific manner in response to insults during development. The term 
‘epigenetics’ was coined in 1942 by Conrad Waddington and was defined as ‘the branch 
of biology that studies the casual interactions between genes and their products, which 
bring the phenotype into being’129. Most recently, Michael K. Skinner has defined 
epigenetics as ‘molecular factors and processes around DNA that are mitotically stable 
and regulate genome activity independent of DNA sequence’130. Epigenetic mechanisms 
essentially influence the long-term expression of a gene by altering the ability of the 
transcriptional machinery to interact with the chromatin environment. One way this can 
be accomplished is by direct DNA methylation via the addition of a methyl group to CpG 
sites on the DNA by members of the DNA methyltransferase family. Traditionally, an 
increase in methylation across CpG sites can impair initiation, elongation or termination 
of a gene. However, this may not always hold true as is the case with expression of 
Insulin-like growth factor-II (Igf-II), which is increased in IUGR offspring due to 
increased intragenic methylation
131
. Animal models have previously demonstrated that a 
change in the environment as a result of an abundance or a limitation of nutrients during 
the period of development alters the expression of a variety of genes involved with DNA 
methylation, including DNA methyltrasnsferases
132-134
. However, very little is known 
about the impact of these alterations in correlation with promoter specific methylation 
status and long-term transcription of genes involved with cholesterol and glucose 
homeostasis in IUGR offspring
135
. At the moment, clinical and animal studies are only 
beginning to demonstrate alterations in promoter specific methylation patterns of key 
genes associated with cholesterol dysregulation and type 2 diabetes in IUGR offspring, 
exclusively at an observational level
128, 136, 137
.  
The second major epigenetic mechanism involves influencing the chromatin environment 
via a number of post-translational modifications. Chromatin is mainly compromised of 
genomic DNA complexed with histone and non-histone proteins. Nucleosomes, the basic 
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building bƒtarlocks of chromatin138, are composed of 146 base pairs of DNA wrapped 
around two copies each of histones H2A, H2B, H3 and H4 which comprise the histone 
octamer
12
. Histones are subject to a wide variety of post-translational modifications at 
over 60 amino acid residues
139
, including methylation, acetylation, phosphorylation, 
ubiquitination and ADP-ribosylation
139, 140
. The combinatorial nature of these covalent 
modifications reveals a “histone code” 139, 140. This code provides for a regulatory system 
that may dictate the transient, as well as long-term, transition between gene silencing or 
activation (Figure 1.3). Amongst all the different types of post-translational histone 
modifications, acetylation and methylation of lysine and phosphorylation of serine and 
threonine residues can be considered as well characterized. This is because their roles 
have been exhaustively examined through genome wide mapping studies which were 
geared towards detecting correlations between histone modification patterns and specific 
states of gene activity
141
. The effects of other types of post-translational histone 
modifications on the overall chromatin structure are poorly understood and are mostly 
analyzed at the descriptive level
141
. Of interest, acetylation and phosphorylation of 
histones have a high turnover rate, with a half life of only a few minutes
142, 143
. In 
contrast, the turnover of histone lysine methylation is much slower and is similar to that 
of the entire histone (~1.3 days)
144
. In addition, the greater the degree of methylation (i.e 
mono, di or tri-methylation), the greater the half-life and more stable the chromatin 
state
144, 145
. Therefore, amongst all of the well characterized post-translational histone 
modifications, the tri-methylation of histone at lysine residues can be regarded as most 
suited towards maintaining long-term gene transcription
140, 146-149
. Genes linked to 
cholesterol and glucose homeostasis can be upregulated or repressed depending on 
changes to the availability and demand of these two products in the body. Therefore, their 
promoter regions are expected to facultatively change from euchromatin to 
heterochromatin states, in order for transcription factors and co-regulators to 
appropriately access the region and exert their transcriptional effects. Therefore, amongst 
all the possible histone lysine residues which are known to be tri-methylated, focus 
should be aimed at those residues which have been previously observed to occur at both 
facultative heterochromatin as well as euchromatin regions of the genomic DNA
150-158
. 
Furthermore, careful consideration should be given on determining which specific lysine 
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residue on the histones is tri-methylated. This is because depending on the type and 
location of the amino acid residue undergoing the posttranslational histone modification, 
one can observe either an increase or a decrease in gene transcription. For instance, an 
increase in the levels of tri-methylation at Histone H3 at lysine 4 and 36 is associated to 
be linked to active transcription. Conversely, if the increase in tri-methylation were to 
occur at Histone H3 lysine at 9 and 27, it would be associated with transcriptional 
repression
159
. 
 It is important to realize that the different prenatal insults which lead to IUGR offspring 
seem to have both common and distinct adaptive responses initiated via epigenetic 
mechanisms. Therefore IUGR offspring derived from different insults may differ or be 
similar due to global, tissue, or site-directed epigenetic modifications. To date, there is 
very little known about the epigenetic alterations associated with expression of target 
genes in the liver throughout normal and abnormal fetal and postnatal development
91, 92, 
160
. Given that LXR has an important role in regulating transcription of genes linked to 
cholesterol homeostasis
113
, it becomes important to evaluate the underlying role of 
epigenetic mechanisms (i.e. DNA methylation and posttranslational histone 
modifications) on regulating the long-term transcription of LXR and its target genes in 
an animal model of IUGR. However, there is limited knowledge about the 
posttranslational histone modifications which alter the activation of LXR target genes. 
One study in chick embryonic hepatocytes has demonstrated that LXR agonists increase 
the transcription of ACCα via increased LXR binding to the LXRE within the 5’ 
upstream region of ACCα along with enhanced acetylation of Histone H3161. In vitro 
studies by Yu et al. have demonstrated that the LXR mediated transcriptional activation 
of the FAS gene was associated with enriched Histone H3 and H4 acetylation at the 
LXRE within 30 minutes of ligand addition
162
.  While these studies suggest that LXR 
target genes are subject to regulation by posttranslational histone modifications, little is 
known about the epigenetic alterations associated with expression of hepatic LXR target 
genes throughout normal or abnormal fetal and postnatal development. One study has 
reported that MPR during pregnancy results in the suppression of LXRα expression in the 
fetal liver as a result of methylation of the upstream region of the LXRα promoter, but 
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effects in postnatal life were not investigated
128
. As such, the influences of epigenetic 
mechanisms on LXR target genes on giving rise to the etiology of the metabolic 
syndrome also deserve consideration. Recently, our laboratory has demonstrated that 
maternal hypoxia during pregnancy leads to enhanced histone H3 methylation [lysine 9] 
surrounding the LXRE region (-258 to -169) of the rat G6Pase promoter by 12 months of 
age
75
, but the effects of under nutrition during perinatal life on long-term LXR activity at 
promoter of its target genes remain elusive. 
Aside from post-translational histone modifications which may govern the long-term 
expression of genes, microRNAs (miRNAs) may also play a key role in the fetal 
programming of cholesterol and glucose homeostasis. miRNAs are short, noncoding 
RNA molecules of 20-25 nucleotides in length that regulate gene expression via 
messenger RNA (mRNA) degradation and/or translational repression
163, 164
. By 
regulating the expression of target genes, miRNAs have been demonstrated to alter a 
variety of physiological processes including cell cycle regulation, differentiation, 
metabolism, and aging
164
. miRNAs silence gene expression by binding to the 3’-
Untranslated Region (3’-UTR) with partial sequence homology to induce cleavage or 
repression of productive translation
165. Given their ability to bind 3’-UTR with partial 
sequence homology, a single miRNA may have multiple targets in the genome
165
. 
Conversely, given the nature of miRNA targeting, a single mRNA transcript can 
theoretically be targeted by several miRNAs
165
. While miRNAs likely play an important 
role in the etiology of adult diseases and cancer, their role in fetal development and 
programming remain elusive. Recent microarray studies employing primers for a variety 
of miRNAs have demonstrated that maternal nutrient restriction can permanently alter the 
expression of miRNAs in the aortas of newborn and aging rat offspring
163
. Moreover, 
circulating hypoxia regulated miRNAs have been demonstrated to be increased in 
pregnant women with fetal growth restriction
166
. The role and identification of miRNAs 
altering the expression of genes involved in the fetal programming of cholesterol and 
glucose homeostasis remain to be identified, but are the subject of great interest. 
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Figure 1.3: Example of how posttranslational modifications to Histone H3 (Lysine 9) 
Leading to Chromatin Remodeling. A variety of histone demethylases can remove the 
methyl group and histone acetyl transferases (HATs) can add an acetyl group to the same 
histone H3 subunit at the Lysine 9 residue leading to an active chromatin environment. 
Conversely, a variety of histone deacetylases (HDACs) can remove the acetyl group and 
histone methyl transferases (HMTs) can add back the methyl group leading to an inactive 
chromatin environment. 
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1.7.3 Role of Sex Hormones in the Early Programming of 
Metabolic Syndrome 
Sex steroid hormones remain an important mediator in long-term regulation of 
cholesterol and glucose in adults. It is well established that the onset and severity of 
numerous adult diseases differ between men and women. For example, men have higher 
24-hour mean blood pressure, by approximately 6 to 10 mm Hg, compared to age 
matched premenopausal women, but this trend reverses after women reach menopause
167
. 
In females, it is hypothesized that differences in sex hormones modulate regulatory 
systems leading to decreased hypertension and vascular dysfunction
167
. Given the 
widespread origins of the metabolic syndrome, it is difficult to assess whether gender 
and, more specifically, sex hormones influence cholesterol catabolism and glucose 
homeostasis. Recent studies in animal models have suggested that perturbations to the 
maternal environment during pregnancy can lead to sex-specific, long-term consequences 
in postnatal life. For example, male offspring of rat dams exposed to 30% global nutrient 
restriction during pregnancy develop hypertension earlier than their female 
counterparts
62
, whereas severe protein restriction (5% protein diet) during pregnancy 
results in programmed hypertension in both sexes
168
.  Moreover, an MPR diet during 
gestation and lactation results in pancreatic  cell dysfunction and visceral obesity 
exclusively in the adult male offspring at postnatal day 130
88, 93
. The sex specificity exists 
even at the epigenetic level in IUGR offspring. For example, uteroplacental insufficiency 
induced IUGR rats at postnatal day 21 have a global increase in the females and decrease 
in the males with respect to acetylation of Histone H3 (Lysine 9, 14) in the hippocampus 
and white matter
169
. In addition, studies have now demonstrated that sex steroid 
hormones can influence epigenetic mechanisms, including post-translational histone 
modifications
170
. Therefore, gender specific differences in the fetal programming of 
cholesterol and glucose homeostasis may be due in part to alterations in their “histone 
code”. 
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1.7.4  ‘Impaired Genesis Model’ in the Early Programming of 
Metabolic Syndrome 
Another important mechanism whereby which early programming of adult diseases can 
occur is via the “impaired genesis model”. After a specific period of development in 
organs such as the brain, kidney and heart, there is a minimal level of replication and 
differentiation potential of the cells from these organs
171-175
. This model suggests that any 
insults during these critical periods permanently alter the function of these organs by 
impacting the amount and quality of the long-lasting cells in these organs. For example, 
the heart of a newborn contains all the cardiomyocyte cells it requires for the rest of 
postnatal life.  At term, 90% of these cardiomyocytes are binucleated and are terminally 
differentiated. As the heart displays limited plasticity after birth
176
, any foreseeable insult 
during its development can cause permanent changes to its overall growth and function, 
which may later manifest into heart dysfunction in adult life. Placental insufficiency 
induced IUGR in sheep has been demonstrated to lead to a permanent increase in 
proportion of mononucleated cardiomyocytes
177
. Similarly, several cases exist where 
IUGR display alterations in terminal composition and quantity of cells from other organs. 
For example, placental insufficiency during the second half of the pregnancy lead to 
IUGR guinea pigs, which have a decrease in the number of neurons in the hippocampus 
and cerebellum
178
, a phenotype which could have a long-lasting impact on normal 
functioning of the hypothalamus-pituitary axis. Studies with both human and animal 
models have provided additional evidence supporting the impaired genesis model by 
demonstrating with use of different techniques that IUGR can lead to a lower number of 
nephrons, permanently programming kidney function
171
. External stresses leading to 
IUGR can also impact pancreatic and muscle function by way of permanently reducing 
pancreatic  cell mass179 and increasing the proportion of type II b muscle fibers which 
are known to contain a lower number of mitochondria
180
. The precise timing of the 
nutritional insult is also a critical factor in defining the overall impact of the impaired 
genesis model. This is primarily because the timing of the insult would have differing 
effects on the development of different organs and hence on disease risks. Moreover, the 
impact of an insult during the different windows of organ susceptibility can also differ 
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between species
174
. Therefore, important consideration should be given when 
extrapolating findings from one species to another.   
1.7.5 Endoplasmic Reticulum Stress in Underlying the Early 
Programming of Metabolic Syndrome 
The endoplasmic reticulum helps maintain cellular function and survival, as it is essential 
for the synthesis, maturation and export of cellular proteins. A variety of insults such as 
hypoxia, nutrient deprivation, ischemia, viral or bacterial infection can result in excessive 
accumulation of misfolded or unfolded proteins in the ER lumen
181
. The accumulation of 
these proteins triggers the activation of the ER stress pathway, which is also referred to as 
the unfolded protein response (UPR)
181
. UPR aims to alleviate ER stress by decreasing 
global protein translation in order to reduce the load of the ER in processing these new 
proteins. A reduction in global protein translation is accomplished by an increase in 
phosphorylation of eukaryotic Initiation Factor (eIF)-2 at Serine (Ser) 51 residue, which 
leads to a rapid reduction in the initiation of mRNA translation
182
. There is also an 
increase in ER chaperone protein levels (i.e. glucose regulated protein Grp78 and Grp94) 
to improve ER’s protein folding capacity183, 184. Furthermore, ER stress induces the 
splicing of a highly conserved unconventional 26 bp intron of the X-box binding protein 
1 (Xbp-1) mRNA, which encodes for a potent transcription factor involved with 
transcriptional upregulation of genes involved in coping with the ER stress
183, 184
. 
Collectively, an increase in phosphorylation of eIF2 (Ser51), Grp94 and Grp78 protein 
levels, and splice variant XBP-1 mRNA level are considered hallmark indicators of 
elevated ER stress. Given the critical role of endoplasmic reticulum in overall cellular 
functions and survival, any stress to the ER would therefore aggravate the symptoms 
associated with the metabolic syndrome.  
Over the last decade researchers have established a critical role of ER stress in giving rise 
to the risk factors, which characterize the metabolic syndrome in adults
185, 186
. 
Predominantly, research has focused on identifying the various components in the ER 
stress pathophysiology that are linked to molecular mechanisms associated with insulin 
resistance and high cholesterol levels
187-193
. An increase in insulin sensitivity associated 
25 
 
 
with weight loss demonstrated a substantial reduction in markers of UPR activation
194
. 
P85α gene, a positive marker of insulin resistance, was demonstrated to bind to and cause 
the nuclear translocation of spliced XBP-1 in an ER stress dependent manner
195
. 
Furthermore, Grp78 has been demonstrated to prevent an increase in phosphorylation of 
Akt1 at Ser 473 residue, a critical downstream event in the insulin signalling pathway
196
. 
With respect to ER stress association with cholesterol dysregulation, translation 
attenuation in ER-stressed cells decreases Insig-1 levels
193
. As a result, SREBP cleavage 
activating protein is released causing the translocation of SREBPs to the Golgi followed 
by proteolysis to generate the active SREBP transcription factors. These transcription 
factors are involved with activating target genes linked to lipid biosynthesis. 
Interestingly, insults such as hypoxia, nutrient deprivation, ischemia, viral or bacterial 
infection that result in ER stress due to an accumulation of misfolded proteins, have also 
been implicated in placental insufficiency induced intrauterine growth restriction (PI-
IUGR)
182
. An elegant study by Yung et al. in 2008 clearly demonstrated a critical role of 
ER stress in placental dysfunction in human IUGR
197
. As placental dysfunction primarily 
results in decreased nutrient and oxygen transport to the fetus
5, 184-187
, one would 
anticipate ER stress to have an adverse effect on the development of IUGR fetal tissues. 
However, few studies have been conducted to investigate the evidence of UPR response 
in IUGR fetal tissues
198
. Moreover, the role of ER stress in linking IUGR offspring to 
increased risk of developing the metabolic syndrome in adulthood remains poorly 
understood. A schematic summary of the major molecular mechanisms underlying the 
early life programming of the metabolic syndrome has been provided in Figure 1.4. This 
schematic allows for an appreciation of the interdependence which may exist between 
these mechanisms, a topic of future investigations.  
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Figure 1.4: Mechanisms underlying the early programming of metabolic syndrome. A 
variety of insults during pregnancy and weaning including hypoxia, dietary deficiencies, 
excess corticosteroids, infection and inflammation can impact important mechanisms 
which have been known to contribute to the pathophysiologies related to the metabolic 
syndrome. These mechanisms included epigenetic modifications, organelle stress, 
endocrine homeostasis and impaired organogenesis. Elucidating some of the 
interdependencies which may exist between these mechanisms, remain a topic of future 
investigations. 
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1.8 The Impact on Drug Metabolism by the Early Programming of 
Metabolic Syndrome 
Several clinical studies have demonstrated a strong inverse association between birth 
weight and metabolic risk factors associated with CVD
46-49, 54, 199, 200
. Animal studies 
provide further support for this association
72, 90, 93, 104, 106, 201
. Therefore, low birth weight 
offspring would be more likely to be under medication (e.g. statins for 
hypercholesterolemia) for the management of symptoms associated with the metabolic 
syndrome. Moreover, use of these drugs would be anticipated to occur at an earlier time 
in their life. This is particularly relevant in cases where low birth weight offspring 
undergo accelerated growth in neonatal life and display these symptoms by adolescent 
age
35, 36, 38-40, 202
. Yet, there is a lack of epidemiological evidence in humans to support the 
notion that there is indeed a higher usage of prescribed drugs in adult individuals that are 
born low birth weight.  
Many clinical factors including age, sex, ethnicity, body mass index, diet (grapefruit and 
other fruit juices), drug interactions, lifestyle and genetics can all impact the 
pharmacokinetics of a drug in an individual
203-208
. Surprisingly, little is known about 
whether low birth weight represents another significant clinical factor that can also alter 
the pharmacokinetics of a drug in adult life. This point deserves consideration because 
low birth weight offspring which experience conditions of limited supply of oxygen and 
nutrients during gestation, display a hallmark adaptive response where the brain is spared 
at the expense of peripheral organs, including the liver. The sparing occurs as a 
consequence of redistribution of blood flow from the peripheral organs (i.e. liver) in an 
attempt to maintain appropriate oxygen and nutrient supply to the brain
209
. As a 
consequence, liver function is impaired in low birth weight infants
210
. Furthermore, 
animal studies of IUGR have demonstrated long-term alterations in liver function
89-92
. 
Since, the majority of prescribed drugs (~75%) are metabolized in the liver
 211
, it is likely 
that low birth weight offspring with impaired liver function would alter the 
pharmacokinetics of drugs in adult life. 
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The cytochrome P450 (CYP) family of enzymes are responsible for metabolizing 75% of 
the drugs which are eliminated by the liver
211
. Reduced intravenous midazolam clearance 
in preterm infants provides indirect evidence suggesting alteration of hepatic CYP 
enzyme activity in low birth weight infants that are 2 to 15 days old
212
. To date, 
intravenous clearance of midazolam is considered the best probe to estimate hepatic 
CYP3A4 activity
213, 214
, an enzyme responsible for approximately 50% of all drugs 
metabolized by CYP family of enzymes
211
. However, there is little known about the 
impact of IUGR in humans on the long-term activity of these drug metabolizing CYP 
enzymes. Recently an animal study by Tajima et. al. in 2012 suggested that impaired 
development can have a long-term impact on drug metabolizing enzymes in the liver
 215
. 
The study clearly demonstrated that when administering a high fat diet to pregnant mice 
there was a decrease in expression and activity of Cyp3a enzyme in the six weeks old 
offspring
 215
. This coincided with the reduced clearance of trizolam, a substrate of 
Cyp3a
215
. Drug metabolizing enzymes, including Cyp3a and drug transporters, which are 
critical for the uptake and efflux of drugs, are known to be regulated by Pregnane X 
Receptor (PXR) and Constitutive Androstane Receptor (CAR). These two orphan nuclear 
receptors heterodimerize with the Retinoid X receptor (RXR), and subsequently bind to 
xenobiotic response elements at the promoter of drug metabolizing enzymes and 
transporter genes
216
. In addition to providing protection from xenobiotic toxicity, recent 
evidence demonstrates a physiologically important role of PXR and CAR in lipid and 
glucose metabolism
217
. Therefore, the hypercholesterolemia and impaired glucose 
tolerance observed in adult IUGR offspring may likely impact PXR and CAR’s ability to 
prevent toxicity from drugs in adult life. Conversely, CAR activation has been 
demonstrated to improve insulin sensitivity via glucose and lipid metabolic pathways
218
. 
However, PXR activation results in an increase in lipogenesis despite its ability to 
decrease gluconeogenesis
217, 219-221
. Not surprisingly, ligand activation of CAR during 
pregnancy has been demonstrated to prevent insulin resistance in offspring from high fat 
diet induced obese pregnant mice
222
. However, the effect of this on drug metabolizing 
enzymes in the liver was not examined. Interestingly, transient activation of CAR during 
neonatal life has been demonstrated to generate a stable epigenetic memory via promoter 
specific posttranslational histone modifications, which facilitate a long-term increase in 
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some of the Cyp drug metabolizing enzymes
223
. Despite the recent evidence that early 
development impacts hepatic drug metabolizing enzymes long-term, there is still little 
known with respect to drug metabolism in adult life of IUGR offspring.   
1.9 Summary 
Numerous clinical and animal studies have provided evidence for an association between 
IUGR and an increased risk of developing cardiovascular disease. It is well established 
that impaired cholesterol and glucose homeostasis can significantly increase the risk of 
developing cardiovascular disease. Yet the mechanisms underlying the long-term 
impairment of cholesterol and glucose homeostasis in IUGR offspring are only beginning 
to be elucidated. Most animal models aim to investigate this by inducing IUGR by way of 
creating a hypoxic or a nutritionally deprived environment during gestation. The 
mechanisms implicated in the cholesterol and glucose homeostasis impairment in IUGR 
may include permanent alterations in organ development, hormone regulation, cellular 
stresses (i.e. endoplasmic reticulum stress), and/or the global or promoter specific 
epigenetic environment. Lastly, considering that IUGR offspring would have a higher 
likelihood to be under medications (e.g. statins for hypercholesterolemia), investigating 
whether alterations in these mechanisms influence their ability to metabolize drugs in 
adult life remains to be determined.  
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2 HYPOTHESIS AND SPECFIC AIMS 
2.1 Focus of the Thesis 
The incidence of metabolic syndrome in Canada is reaching epidemic proportions, with 
one in three Canadian family-practice patients between 40 and 60 years of age falling 
under this criterion
1
. Adults with the metabolic syndrome have a ~20-fold risk for 
developing cardiovascular disease(CVD)
1
, a leading cause of premature death world 
wide. Most notably, impaired regulation of cholesterol and glucose can lead to a 
significant increased risk of developing CVD
2, 3
. Several clinical studies have 
demonstrated that intrauterine growth restriction (IUGR) offspring, faced with a 
nutritional mismatch postpartum, have an increased risk of developing an atherogenic 
lipid profile and insulin resistance
4-10
.  Maternal protein restriction (MPR) rat model has 
been extensively studied to investigate the adverse effects of a nutritional mismatch in 
postnatal life of IUGR offspring. The function of the liver, an important metabolic organ, 
has been previously reported to be impaired in the MPR derived offspring
11-14
. However 
the underlying mechanisms, which predispose these offspring to cholesterol 
dysregulation and insulin resistance, remain elusive. The overall hypothesis of this thesis 
is that long-term alterations in the liver of IUGR offspring may mediate cholesterol 
dysregulation in adult life. The focus of the thesis is to identify alterations to key 
molecular mechanisms in the liver of MPR derived offspring that may lead to cholesterol 
dysregulation in adulthood. The thesis will also evaluate the ‘thrifty phenotype’ 
hypothesis with respect to whether these alterations become more harmful in conditions 
where the MPR derived IUGR offspring are faced with a nutritional mismatch in 
postnatal life. Moreover, the impact of this on the long-term ability to metabolize drugs in 
the liver will also be determined.  
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2.2 Specific Aim 1 
To determine whether maternal protein restriction elevated cholesterol in adult rat 
offspring via repressive changes in histone modifications at the Cholesterol 7-
Hydroxylase promoter.  
Adverse events in utero, such as intrauterine growth restriction (IUGR), can permanently 
alter epigenetic mechanisms leading to the metabolic syndrome, which encompasses a 
variety of symptoms including augmented cholesterol. The major site for cholesterol 
homeostasis occurs via the actions of hepatic cholesterol 7-hydroxylase (Cyp7a1), 
which catabolizes cholesterol to bile acids. Post-translational histone modifications have 
been previously demonstrated to regulate Cyp7a1 transcription in adult mice
15-17
.  In 
Chapter 3, we sought to determine whether posttranslational histone modifications 
influence the long-term expression of Cyp7a1 in IUGR.  
 
Using a maternal protein restriction rat model we hypothesized that IUGR offspring may 
lead to elevated cholesterol in adult offspring via repressive changes in histone 
modification at the Cyp7a1 promoter. We describe in Chapter 3 that a low protein diet 
during pregnancy and lactation led to IUGR offspring with decreased liver to body 
weight ratios, followed by increased circulating and hepatic cholesterol levels in both 
sexes at day 21 and exclusively in the male offspring at day 130. The augmented 
cholesterol was associated with decreases in the expression of Cyp7a1. Chromatin 
immunoprecipitation (ChIP) revealed that this was concomitant with diminished 
acetylation and enhanced methylation of histone H3 [K9,14], markers of chromatin 
silencing, surrounding the promoter region of Cyp7a1.  These epigenetic modifications 
originate in part due to dietary-induced decreases in fetal hepatic Jmjd2a expression, a 
histone H3 [K9] demethylase. Collectively, these findings suggest that the augmented 
cholesterol observed in low protein diet derived offspring is due to permanent repressive 
posttranslational histone modifications at the promoter of Cyp7a1. Moreover, this was the 
first study to demonstrate that maternal undernutrition leads to long-term cholesterol 
dysregulation in the offspring via epigenetic mechanisms.  
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2.3 Specific Aim 2 
To determine whether nutritional mismatch in postnatal life of low birth weight 
offspring leads to elevated hepatic endoplasmic reticulum stress in adulthood.  
Several clinical studies have demonstrated that low birth weight offspring, as a result of 
an adverse in utero environment, have an increased risk of developing the metabolic 
syndrome. Moreover, this risk is further exasperated when the low birth weight offspring 
is faced with a “nutritional mismatch” in the predictive postnatal environment. In rodent 
models, maternal protein restriction derived IUGR offspring when faced with a 
nutritional mismatch to normal protein in postnatal life have been previously 
demonstrated to result in impaired fetal growth, glucose intolerance and 
hypercholesterolemia (Chapter 3) in adulthood
18-20
. Interestingly, there is strong evidence 
linking endoplasmic reticulum (ER) stress to both increased cholesterol and insulin 
resistance in adults
21-29
. In Chapter 4, we sought to determine whether ER stress plays a 
role in predisposing low birth weight offspring to greater risk of metabolic syndrome.  
Therefore, we hypothesized that MPR derived offspring faced with a nutritional 
mismatch are at a higher risk of developing metabolic syndrome in adult life due to 
presence of elevated hepatic ER stress. To address this hypothesis, pregnant Wistar rats 
were fed a control 20% protein diet (C) or a low 8% protein diet during pregnancy and 
postnatal life (LP1), during pregnancy and lactation (LP2), or exclusively during 
pregnancy (LP3). We describe in Chapter 4 that the LP2 and LP3 offspring which 
received a “nutritional mismatch” postpartum, displayed an elevation of established ER 
stress markers in the liver, including an increase in X box binding protein 1 mRNA 
splicing levels and elevated ER chaperones (Glucose regulated protein 78 and 94) at 
postnatal day 130. This was concomitant with attenuated protein synthesis, as indicated 
by increased phosphorylation of eukaryotic initiation factor 2 at Ser 51 residue. 
However, those offspring that were maintained on low protein diet postpartum (LP1) did 
not display elevated ER stress markers. These findings highlight a novel role of ER stress 
in predisposing low birth weight offspring, faced with a postnatal “nutritional mismatch”, 
to increased risk of developing the metabolic syndrome. 
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2.4 Specific Aim 3 
To determine whether nutritional mismatch in postnatal life of low birth weight 
offspring leads to altered hepatic drug metabolism in adulthood.  
Strong clinical evidence exists to support an association between low birth weight and 
increased risk of developing the metabolic syndrome. In rodent models, we have 
previously demonstrated that maternal protein restriction (MPR) results in impaired fetal 
growth and hypercholesterolemia in adulthood (Chapter 3)
18
. This was attributed to the 
long-term repression of hepatic cholesterol 7α-hydroxylase (Cyp7a1), a rate-limiting 
enzyme that catabolizes cholesterol to bile acids.  Interestingly, decreased Cyp7a1 
expression is associated with Endoplasmic Reticulum (ER) stress in a rat model of 
Hypothyroidism
30
. Moreover, we have recently demonstrated ER stress markers to be 
elevated in the livers of adult MPR offspring (Chapter 4). As cytochrome p450 dependent 
(Cyp) enzymes reside in the ER of the liver and are the primary enzymes involved with 
Phase 1 of drug metabolism, in Chapter 5 we investigated whether their ability to 
metabolize substrates is altered in adult life of MPR derived low birth weight offspring.  
Therefore, we hypothesized that MPR offspring may have an impaired ability to 
metabolize drugs in adulthood. To address this hypothesis, pregnant Wistar rats were 
either fed a control 20% protein diet (Control) or a low 8% protein diet throughout life 
(LP1) or exclusively during pregnancy and lactation (LP2). We describe in Chapter 5 that 
the Cyp3a, Cyp2b and Cyp2c enzymatic activity (Vmax/Km) increased at postnatal day 
130, as evaluated by testosterone enzyme kinetics in liver microsomes via ultra 
performance liquid chromatography. The increase in activity was associated with an 
increase in mRNA levels of Cyp3a1, Cyp2c11, Cyp2b1 as determined through Q-RT-
PCR. This correlated well with an increase in expression of constitutive androstane 
receptor, which is known to regulate transcription of these Cyp enzymes. Collectively, 
these findings suggest that a low birth weight offspring may require greater amount of 
drugs which are metabolized by Cyp3a, Cyp2b and Cyp2c enzymes in order to exert their 
therapeutic effect. This is an extremely relevant finding as it is applicable to those 
individuals who are more likely to be prescribed medication (e.g. statins for 
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hypercholesterolemia) for the management of the symptoms associated with this 
syndrome. 
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3 MATERNAL PROTEIN RESTRICTION ELEVATES 
CHOLESTEROL IN ADULT RAT OFFSPRING DUE TO 
REPRESSIVE CHANGES IN HISTONE MODIFICATIONS AT THE 
CHOLESTEROL 7-HYDROXYLASE PROMOTER2 
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Maternal protein restriction elevates cholesterol in adult rat offspring due to repressive changes in histone 
modifications at the cholesterol 7alpha-hydroxylase promoter. Mol Endocrinol 25(5): 785-98. 
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3.1 Introduction 
High circulating cholesterol, in addition to hypertension, central obesity, and insulin 
resistance characterize the metabolic syndrome, and remains an important cardiovascular 
risk factor in adults
1, 2
. The major site for the regulation of cholesterol homeostasis occurs 
in the liver, mainly through the conversion of cholesterol to bile acids, via the rate 
limiting enzyme cholesterol 7α-hydroxylase (Cyp7a1)3.  The expression of Cyp7a1 is 
under the regulation of the orphan nuclear receptor, the Liver X Receptor (LXR)
4
. Male 
and female mice deficient in Cyp7a1 have elevated circulating cholesterol and decreased 
LDL receptors, collectively leading to a ‘proatherogenic’ phenotype5. While current 
therapies using the statin class of lipid-lowering drugs have been successful in treating 
patients with high cholesetrol
6
, some patients experience adverse side effects such as 
rhabdomyolysis
7
. Thus, additional novel strategies are warranted to prevent the onset of 
hypercholesterolemia and reduce the long-term use of these drugs. 
 
Clinical studies in humans have demonstrated that adverse events in utero that result in 
placental insufficiency-induced intrauterine growth restriction (PI-IUGR, representing 
8% of newborns), can also alter physiological processes leading to the metabolic 
syndrome
8, 9
. Moreover, 50% of metabolic syndrome-related diseases can be linked to 
adverse events in utero
10-12
. With respect to cholesterol, David Barker and colleagues 
have demonstrated that impaired fetal growth is linked to elevated LDL cholesterol and 
hypertension in adult humans
13, 14
.  Moreover, the association between birth weight and 
cholesterol was more apparent in males and independent of social class, current body 
weight, cigarette smoking, and alcohol consumption
13
. Given that hypercholesterolemia 
in mothers is associated with increased incidence of aortic fatty-streaks in fetal and 
adolescent life
15
, it is conceivable that postnatal cholesterol concentrations may be altered 
by the perinatal environment, though the underlying molecular mechanisms are unknown.  
 
Various animal models have broadened our understanding of how early nutrition in 
pregnancy may influence liver development
16-19
. The majority of studies have 
demonstrated that maternal nutrient or protein restriction leads to decreased liver 
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growth
16-19
. Other studies have demonstrated that a low protein diet during pregnancy 
leads to asymmetrical IUGR
20
, associated with alterations in hepatic glucose output, 
decreased glucagon receptor and glucokinase expression, along with increases in insulin 
degradation and hepatic lobular volume
16, 17
. However, very little is known about how 
maternal nutrition may alter cholesterol homeostasis in postnatal life. In one study, 
maternal dietary iron restriction led to a 21% decrease in fetal growth and an increase in 
fetal liver cholesterol
21
. This was further associated with decreased expression of 
Cyp7a1
21
. More recently, a low protein diet throughout pregnancy in mice was 
demonstrated to lead to reduced LXRα expression at embryonic day 19.522, however the 
long-term effects of this in utero nutritional insult on cholesterol homeostasis in postnatal 
life remain elusive. 
 
Although transcriptional changes may mediate the expression of target genes involved in 
fetal programming, there is limited knowledge on the links between epigenetic 
mechanisms in utero and the long-term expression of hepatic target genes 
18, 19, 23, 24
. 
Previous studies have demonstrated that diminished acetylation and/or an increased 
methylation of histone H3 [K9,14] has been associated with chromatin silencing and 
decreased RNA Polymerase II binding
25, 26
. Elegant studies by Park et al. have 
demonstrated that uterine-ligation induced IUGR rat offspring developed type 2 diabetes 
as a result of epigenetic silencing of pancreatic and duodenal homeobox 1 (Pdx1), a 
critical transcription factor regulating β cell differentiation27. This included both 
deacetylation and hypermethylation of histone H3[K9]
27
. Recently it was demonstrated 
that in a model of a low protein diet during pregnancy, LXRα expression was suppressed 
in the fetal liver as a result of DNA hypermethylation at the LXRα promoter22, however 
the long-term effects of this diet on LXR-target genes (e.g. Cyp7a1) in postnatal life were 
not examined.  In addition, the effects of a low protein diet on posttranslational histone 
modifications during liver development have never been explored.  
 
In the present study, we tested the hypothesis that a low protein diet in pregnancy may 
impair cholesterol homeostasis long-term via repressive changes to histone modifications 
throughout development in a promoter-specific manner. We observed whether the timing 
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of the low protein diet throughout pregnancy and lactation led to increases in circulating 
cholesterol in both early (3 weeks) and late (18 weeks) postnatal life. To accomplish this, 
four dietary regimes (Control, C; Low Protein, LP1-LP3) were employed to assess the 
effects of a low protein diet throughout life (LP1), until the end of lactation (LP2), and 
exclusively during gestation (LP3). By examining all three low protein dietary regimes, it 
is possible to assess the impact of the duration of the low protein diet and the timing of 
protein restoration on liver development and circulating cholesterol.  Given that Cyp7a1 
plays a major role in regulating cholesterol catabolism in the liver, we also demonstrated 
if changes in circulating cholesterol were linked to alterations in Cyp7a1 expression. 
Finally, we investigated whether any changes to Cyp7a1 expression in fetal and postnatal 
life were due to differences in the acetylation and trimethylation of histone H3 [K9] 
surrounding the Cyp7a1 promoter.  
3.2 Materials and Methods 
3.2.1 Animals and Dietary Regimes 
All procedures were performed in accordance with the guidelines set by the Canadian 
Council of Animal Care and upon approval of the Animal Care Committee of the 
University of Western Ontario. Female and male Wistar rats at breeding age (250 g) were 
purchased from Charles River (La Salle, St-Constant, Quebec, Canada). These rats were 
housed in individual cages and maintained at room temperature on a 12:12 hour light-
dark cycle. For three weeks, these rats were left to acclimatize to the animal care facility 
and their reproductive cycles were followed. At the onset of pro-estrous, these rats were 
mated. Impregnation was confirmed by the presence of sperm in the vaginal smear the 
next morning. 
At the onset of proestrus, these rats were mated. Impregnation was confirmed by the 
presence of sperm in the vaginal smear the next morning. Upon confirmation of 
impregnation (gestation day 1), the rats were fed either a control diet containing 20% 
protein (Bio-Serv, Frenchtown, NJ, USA, Product# F4576 – Rodent Diet, AIN-93G, 
Blue, ½” pellets) or a LP diet containing 8% protein (Bio-Serv, Frenchtown, NJ, USA, 
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Product#F4575 – Rodent Diet, AIN-93G, ½” pellets). The LP diet contained similar fat 
content and was made isocaloric (3.61 kcal/gram for control and 3.66 kcal/gram for LP 
diet) by the addition of carbohydrates (Bio-Serv, Frenchtown, NJ, USA).  
At birth, the litter size was reduced to 8 animals (4 females and 4 males), with weights 
closest to the litter mean. This ensured a standard litter size for all mothers. Four different 
dietary regimes were administered to these offspring (Table 3.2). Offspring derived from 
a maternal low protein diet were either administered the low protein diet throughout 
postnatal life (LP1), until the end of lactation (LP2) or until birth (LP3). Otherwise, they 
were given a control diet. 
Food and water was provided ad libitum and food intake was recorded during pregnancy 
and in the offspring. At embryonic day 19 (e19), a subset of pregnant rats were sacrificed, 
and the weights of the fetus, placenta and liver were measured, and the fetal liver was 
excised and frozen. Another subset of rats was allowed to deliver spontaneously. The 
growth curves and food intake of these offspring were monitored by measuring their 
body weight and food consumption every third day. At both postnatal day 21 (d21), the 
selected time for weaning, and at postnatal day 130 (d130), the pups were also sacrificed 
for blood and medial lobe liver tissue analysis.  
3.2.2 Plasma Lipid Measurements 
Measurements of total cholesterol and triglycerides from plasma of all blood samples was 
automatically detected using the COBAS
®
 analyzer (Roche, Mississauga, Ontario, 
Canada) at St. Joseph’s Health Care (London, Ontario, Canada). For the measurement of 
circulating cholesterol, cholesterol esters were cleaved by cholesterol esterase and 
subsequently converted to cholest-4-en-3-one and hydrogen peroxide by cholesterol 
oxidase. A colorimetric assay resulting from breakdown of hydrogen peroxide via the 
Trinder reaction allowed for the quantification of cholesterol levels.  
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3.2.3 Hepatic Cholesterol Measurements 
In order to determine the total amount of cholesterol present in hepatic tissue, a (1:1) 
chloroform:methanol extraction was performed in order to extract and separate total 
cholesterol and phospholipids from aqueous matter. After samples were dried, the total 
amount of cholesterol was determined by the Amplex®Red Cholesterol Assay Kit 
(Invitrogen, Carlsbad, CA, USA) which produces resorufin as a cholesterol by-product. 
This was measured using a fluorescence spectrometer at 590 nm.  
3.2.4 Real Time PCR Analysis 
Total RNA from Wistar rat medial lobe liver tissue was extracted at e19, d21 and d130 
by the one-step method of Chomczynski and Sacchi
28
 (TRIzol, Invitrogen, Carlsbad, CA, 
USA). RNA was treated with deoxyribonuclease to remove any contaminating DNA. 4 
µg of the total RNA was reverse transcribed to cDNA using random primers and 
Superscript II RNase H-reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Primer 
sets directed against rat Jmjd2a, Jmjd2c, Jmjd2d, β-actin, and Hprt (ribosomal RNA) 
were generated via Primer Express software (PE Applied Biosystems, Boston, MA, USA) 
based on published sequences (Table 3.1). The relative abundance of each transcript was 
determined by real-time quantitative PCR as previously published
29
. For the quantitative 
analysis of mRNA expression, the Bio-Rad CFX384 Real Time System was employed 
using the DNA binding dye IQ
TM
 SYBER green supermix (Bio-Rad, Mississauga, 
Ontario, Canada). The cycling conditions were 50 C for 2 min, 95 C for 10 min, followed 
by 45 cycles of 95 C for 15 sec, and 60 C for 1 min. The cycle threshold was set at a level 
where the exponential increase in PCR amplification was approximately parallel between 
all samples. All primer sets produced amplicons of the expected size and sequence. We 
calculated the relative fold changes using the comparative cycle times (Ct) method with 
ribosomal RNA (Hprt) or β-actin as the reference guide. Over a wide range of known 
cDNA concentrations, all primer sets were demonstrated to have good linear correlation 
(slope=-3.4) and equal priming efficiency for the different dilutions compared with their 
Ct values (data not shown). Given that all primer sets had equal priming efficiency, the 
∆Ct values (primer internal control) for each primer set were calibrated to the 
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experimental samples with the lowest transcript abundance (highest Ct value), and the 
relative abundance of each primer set compared with calibrator was determined by the 
formula, 2
∆∆Ct, in which ∆∆Ct is the calibrated Ct value. 
3.2.5 Chromatin Immunoprecipitation (ChIP) 
ChIP was performed on snap frozen medial lobe liver tissue excised at e19, d21 and d130 
from male and female offspring derived from the Control or LP2 dietary regime. ChIP 
was performed using a modification
30
 of previously published methods
31
. Briefly, a small 
piece of snap frozen liver was homogenized and incubated with 1% formaldehyde for 10 
min at room temperature to cross-link proteins and DNA. Crosslinking was terminated by 
the addition of Glycine (0.125M, final concentration). The liver tissue was washed once 
with cold PBS and placed in 500 l of SDS lysis buffer (Millipore, Etobicoke, Ontario, 
Canada) with protease inhibitor cocktail (Roche, Mississauga, Ontario, Canada). The 
lysates were sonicated on ice to produce sheared, soluble chromatin. The lysates were 
diluted ten times with the addition of ChIP dilution buffer (Millipore, Etobicoke, Ontario, 
Canada) and aliquoted to 400 l amounts. Each of the aliquots was precleared with 
protein A/G Plus agarose beads (40 µl, Millipore, Etobicoke, Ontario, Canada) at 4°C for 
30 minutes. The samples were microfuged at 12500 rpm to pellet the beads, and the 
supernatant containing the sheared chromatin was placed in new tubes. The aliquots were 
incubated with 4 µg of antibodies against RNA Polyermase II (cat #05-623B), acetylated 
histone H3 (lysine 9,14, cat #05-399), trimethylated histone H3 (lysine 9, cat# 07-442, all 
from Millipore, Etobicoke, Ontario, Canada), or Liver X Receptor (LXR, cat# sc-
13068x, Santa Cruz Biotechnology, Santa Cruz, California) at 4°C overnight. Two 
aliquots were reserved as ‘controls’ – one incubated without antibody and the other with 
non-immune IgG (Millipore, Etobicoke, Ontario, Canada). Protein A/G Plus agarose 
beads (60 l) were added to each tube, the mixtures incubated for 1 h at 4°C and the 
immune complexes collected by centrifugation. The beads containing the 
immunoprecipitated complexes were washed sequentially for 5 min in wash buffer I (20 
mM Tris-HCl, pH 8.1, 2 mM EDTA, 0.1% SDS, 1% Triton X-100, 150 mM NaCl), wash 
buffer II (same as I, except containing 500 mM NaCl), wash buffer III (10 mM Tris-HCl, 
pH 8.1, 1 mM EDTA, 1% NP-40, 1% deoxycholate, 0.25 M LiCl), and in 2  TE buffer. 
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The beads were eluted with 250 l elution buffer (1% SDS, 0.1mM NaHCO3 + 20 g 
salmon sperm DNA (Sigma-Aldrich, Oakville, Ontario, Canada) at room temperature. 
This was repeated once and eluates were combined. Crosslinking of the 
immunoprecipitated chromatin complexes and ‘input controls’ (10% of the total soluble 
chromatin) was reversed by heating the samples at 65C for 4 h. Proteinase K (15 µg, 
(Invitrogen, Carlsbad, CA, USA) was added to each sample in buffer (50 mM Tris-HCl, 
pH 8.5, 1% SDS, 10 mM EDTA) and incubated for 1 h at 45C. The DNA was purified 
by phenol-chloroform extraction and precipitated in EtOH overnight at 20C. Samples 
and ‘input’ controls’ were diluted in 10-100 l TE buffer just prior to PCR. Real-time 
PCR was employed using forward (5’-TGCTTTGGTCACTCAAGTTCA-3’) and reverse 
(5’-GCAATTCCCCAAATCAAAGA-3’) primers that amplify a -164 bp to +65 bp 
region encompassing the TATA box and the Cyp7a1 initiation site
32, forward (5’-
CGTAGCTCAGGCCTCTGCGCCCTT-3’) and reverse (5’-CTGGCACTGCAC-
AAGAAGATGCGGCTG-’) primers that amplify a -123 bp to +53 bp region 
encompassing the TATA box and the rat Gapdh initiation site
33, and forward (5’-
GGCCGGGTAATGCTATTTTT-3’) and reverse (5’-CCGAAACAGTGGGTCTGACT-
3’) primers that amplify a -156 bp to +25 bp region encompassing the rat Cyp7a1 LXRE 
site (-128 bp to -81 bp) and the TATA box (PE Applied Biosystems, Boston, MA, 
USA)
32
. Using serial dilutions of rat liver chromosomal DNA, these primers were 
employed because this region has equal efficiency in priming to their target sequences. 
Primers against distal regions of the Cyp7a1 promoter were employed to ensure this 
region has the greatest recruitment of RNA Polymerase II. 
3.2.6 Preparation of Tissue Membrane Extracts and Immunoblot 
Analysis 
Wistar rat liver tissue membrane extracts were prepared using modifications of 
previously published methods
34
. Briefly, a small piece of snap frozen medial lobe liver 
tissue was homogenized in a 1.2 ml of buffer A solution (250mM Sucrose, 2mM MgCl2, 
20mM Tris-HCl at overall pH 7.5) with protease inhibitor cocktail (Roche, Mississauga, 
Ontario, Canada). The homogenate was centrifuged at 2000 g for 10 min at 4
0
C. The 
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supernatant was retained and buffer A was added. This was centrifuged at 120,000 g for 
45 min at 4
0
C and the pellet was retained as the membrane fraction which was 
resuspended in 200 ul of buffer B (80 mM NaCl, 2mM CaCl2, 1% Triton X-100, 50mM 
Tris-HCl at overall pH 8) with protease inhibitor cocktail (Roche, Mississauga, Ontario, 
Canada). Equal concentrations of membrane proteins normalized by colorimetric BCA 
Protein Assay (Pierce Corp., Madison, WI, USA), were fractionated in gradient 
polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) and transferred onto PVDF 
membrane (Millipore, Etobicoke, Ontario, Canada). Blots were probed using Cyp7a1 
rabbit polycolonal antibody (1:500, cat #sc-25536, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), LXR (Liver X Receptor (cat# sc-13068x, Santa Cruz Biotechnology, 
Santa Cruz, California) and monoclonal HRP conjugated β-Actin (1:50,000, cat#A3854, 
Sigma-Aldrich, Oakville, Ontario, Canada) diluted in 5 % milk-1xTris-buffered saline-
Tween 20 buffer and with horseradish peroxidase conjugated donkey anti-rabbit IgG 
(1:10,000, cat#711-035-152, Jackson ImmunoResearch Laboratories, West Grove, PA, 
USA) diluted in 5 % milk-1x Tris-buffered saline-Tween 20 buffer as the secondary 
antibody. Immunoreactive bands were visualized using an enhanced chemiluminescence 
detection system (Thermo Scientific, Waltham, MA, USA). 
3.2.7 Statistics 
All results were expressed as the mean of arbitrary values  the standard error of the 
mean (SEM). The significance of differences (p<0.05) between mean values were 
evaluated using the unpaired Student’s t-test for results from qRT-PCR, ChIP and 
Immunoblot analysis. Two and one-way analysis of variance (ANOVA) followed by a 
Bonferroni’s Multiple Comparison post hoc test, was used to evaluate significance of 
differences for results comparing the effect of all the dietary regimes. 
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Table 3.1. Real Time PCR primers 
Gene Primer (5’-3’) Reference No. 
Jmjd2a FWD GCG AGC AGG AGC TGG CAG AG NM 001107966 
REV AAC ACC AGC GGG TGA TGG CG NM 001107966 
Jmjd2b FWD GCG AGC TGG TGG AGC TGC GG  BC161813 
REV GGG ACC GTA CCC TCT TGG GC  BC161813 
Hmg-CoA 
Reductase 
FOR TAC ATC CGT CTC CAG TCC AAA A NM 013134 
REV CAG GTT TCT TGT CGG TGC AA NM 013134 
Ldlr FOR GGG TTC CAT AGG GTT TCT GCT NM 175762 
REV TGG TAT ACT CGC TGC GGT CC NM 175762 
Jmjd2c FWD ATG GAG GAG TTT CGG GAG TT BC158850  
REV CAT GGG CTT TTT CTG GAT GT BC158850 
Jmjd2d FWD GGG GCA GCC ACG AGC TTT CC NM 001079712 
REV  GGG CAT CAG CTC AGT CAG GG NM 001079712 
Hprt FWD TTG CTC GAG ATG TCA TGA AGG A NM 012583  
REV  AGC AGG TCA GCA AAG AAC TTA TAG NM 012583 
β-actin FWD ACG AGG CCC AGA GCA AGA NM 031144 
REV TTG GTT ACA ATG CCG TGT TCA NM 031144 
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3.3 Results 
3.3.1 A low protein diet during pregnancy and lactation leads to 
impaired body weight and liver growth 
A low protein diet during pregnancy has been previously demonstrated to decrease birth 
weight
16-19
 and lead to increases in visceral fat, impaired glucose tolerance, and 
symptoms of type II diabetes in adulthood
35-38
 in the rat offspring. Although others have 
demonstrated that offspring derived from this low protein dietary regime were not 
hypertensive at 4 weeks of age
39
, low protein females placed on a high carbohydrate diet 
after lactation exhibited elevated systolic blood pressure at 1 year of age
40
.  In this study, 
a low protein diet resulted in a significant decrease in fetal to placental weight ratio and a 
marked decrease in fetal liver to body weight ratio at embryonic day 19 (Table 3.2). In 
agreement with previous reports
41, 42
, a low protein diet did not alter maternal food intake 
and there was no observed change in litter size or sex ratio (Figure 3.1A). To further 
examine the effect of the timing and duration of the low protein diet on postnatal growth 
and liver development, various dietary regimes (LP1, LP2, LP3) were implemented 
(Table 3.2). At day 21, there was a significant decrease in both body weight and liver to 
body weight ratio in the male and female offspring derived from the LP1/LP2 diet 
compared to control (Table 3.2). However, offspring of either sex derived from the LP3 
dietary regime displayed no difference in body weight and liver to body weight ratios 
when compared to the offspring derived from the control diet. We next observed the 
effects of LP1-LP3 on liver and body growth at 130 days of age. We examined this age 
based on our previous study which demonstrated sex-specific differences in glucose 
homeostasis at this time point
42
. While the body weights of LP1 or LP2 male and female 
offspring regimes remained significantly lower at day 130, their liver to body weight ratio 
was restored compared to the control animals (Table 3.2). Furthermore, no change in the 
food intake of the offspring was observed in the four dietary regimes (C, LP1-3; data not 
shown), suggesting that it was a difference in the protein content of the diet and not 
appetite that was a primary factor in inducing any of the observed developmental 
changes.  
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Table 3.2. The effect of LP dietary regimes LP1, LP2, LP3 on liver growth and body 
weight in rat offspring at embryonic day 19 (e19), postnatal day 21 (d21), and postnatal 
day 130 (d130) 
 
 
Dietary regimes and the liver to body weight ratio of offspring. To assess body weight 
(g), the fetal to placental weight ratio was determined for offspring killed at e19, and the 
body weight was determined for offspring killed at d21 and d130. To assess liver growth, 
liver to body weight ratio was determined for all three developmental time points. All 
data was expressed as SEM. For e19, dietary effects were determined using Student’s 
unpaired t test whereas for d21 and d130, a one-way ANOVA followed by a Bonferroni’s 
Multiple Comparison post hoc test was performed. 
a 
= Significant difference (P < 0.05) 
vs. control (n = 10–14/group). N/A refers to when the LP dietary regimes were the same. 
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Figure 3.1: Effect of maternal low protein diet on A. Maternal Food Intake and B. 
Maternal Weight. Pregnant rats were given either a control diet (20% protein) or a low 
protein diet (8% protein) during gestation. Weight of food eaten in g/day/animal and 
maternal weight gain from gestation day 1 to gestation day 22 in grams were measured, 
respectively. Results were expressed as the mean ± SEM.* = significant difference 
(p<0.05). n=4-6/group, where each n represents a different mother. 
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3.3.2 A low protein diet during pregnancy and lactation leads to 
augmented circulating cholesterol in both sexes in early 
development, and exclusively in the male offspring in 
adulthood 
To determine whether LP1-LP3 led to postnatal changes in cholesterol levels, total 
circulating cholesterol was measured in the offspring at day 21 and day 130 . Total 
circulating cholesterol levels was observed to be significantly increased in the male and 
female offspring derived from the LP1/LP2 dietary regime at day 21 (Figure 3.2A) and 
exclusively in the male offspring derived from the LP2 dietary regime at day 130 (Figure 
3.2B). In addition, hepatic total cholesterol concentrations were similarly increased in 
male LP2 offspring at day 130 (Figure 3.2C). In a small cohort of control animals given a 
low protein diet from birth to day 21 (reverse LP3), circulating cholesterol was not 
significantly different from the control or LP3 offspring (Figure 3.2A). The increase in 
hepatic cholesterol in LP2 males at day 130 was not attributed to alterations in Hmg-CoA 
reductase or the LDL receptor (Figure 3.3). Furthermore, when plasma triglycerides were 
measured at day 21 and day 130, there was no statistical difference in triglyceride 
concentrations between any dietary groups at both ages (data not shown). 
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Figure 3.2: The effect of different low protein dietary regimes on A. circulating 
cholesterol concentrations (mM) in rat offspring at postnatal d 21 (n=10-14/group), B. 
postnatal d 130 (n=10-14/group). C. The effect of LP2 on median lobe liver total 
cholesterol at postnatal d 130 (n=5-6/group). Results were expressed as the mean ± SEM. 
Dietary effects were determined using a two-way analysis of variance (ANOVA) 
followed by a Bonferroni’s Multiple Comparison post hoc test. ** = significant 
difference (p<0.01) & * = significant difference (p<0.05) vs male control, ## = 
significant difference (p<0.01) vs female control. 
72 
 
 
 
Figure 3.3: The effect of the LP2 dietary regime on hepatic 3-Hydroxy-3-methylglutaryl-
coenzyme A reductase (Hmg-CoA reductase) and low-density lipoprotein receptor (Ldl 
receptor) in A, C male and B, D female rat offspring at postnatal d 130, respectively. 
Relative hepatic Hmg-CoA reductase and Ldl receptor protein levels were determined 
using Western blot analysis. Total protein was isolated and Hmg-CoA reductase and Ldl 
receptor protein was detected on a western blot using the Hmg-CoA reductase and Ldl 
receptor primary antibody. The Hmg-CoA reductase and Ldl receptor protein levels were 
quantified using densitometry and normalized to that of β-actin protein levels. Results 
were expressed as the mean ± SEM.* = significant difference (p<0.05). n=5-6/group, 
where each n represents a single offspring derived from a different mother. 
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3.3.3 Decreases in Cyp7a1 protein levels coincide with the 
respective increases in total circulating cholesterol levels in 
offspring derived from the LP2 dietary regime at day 21 and 
day 130 
To elucidate the underlying mechanisms for the augmented cholesterol in the LP2 
offspring, immunoblot analysis was performed to determine the protein levels of hepatic 
Cyp7a1, the rate limiting enzyme involved in the conversion of cholesterol to bile acids, 
during fetal and postnatal development. At embryonic day 19, a low protein diet led to a 
significant decrease in hepatic Cyp7a1 protein levels (Figure 3.4A). At day 21, both the 
male and female offspring derived from the LP1/LP2 dietary regime also had 
significantly lower Cyp7a1 protein levels (Figure 3.4B,C), which was associated with the 
augmented circulating cholesterol observed in both sexes at this age (Figure 3.2A). 
Interestingly, when maternal proteins were restored to the low protein offspring during 
lactaction (LP3), Cyp7a1 protein levels significantly increased compared to control 
(Figure 3.4D). Finally, when the expression of hepatic Cyp7a1 was examined in both 
sexes from the LP2 dietary regime at day 130, only the male LP2 offspring exhibited 
significant decreases in Cyp7a1 protein levels (Figure 3.4E,F). This gender-specific 
decrease in Cyp7a1 coincided with changes in circulating and hepatic cholesterol at this 
age (Figure 3.2B,C). 
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Figure 3.4. The effect of the LP2 dietary regime on hepatic Cyp7a1 protein levels in rat 
offspring at embryonic d 19 (A), male (B), and female (C) rat offspring at postnatal d 21 
and male (E) and female (F) rat offspring at postnatal d 130. (D) The effect of LP3 
dietary regime on hepatic Cyp7a1 protein levels in male rat offspring at postnatal d 21. 
Relative hepatic Cyp7a1 protein levels were determined using Western blot analysis. 
Total membrane protein was isolated and Cyp7a1 protein was detected on a Western blot 
using the Cyp7a1 primary antibody. The Cyp7a1 protein level was quantified using 
densitometry and normalized to that of β-actin protein levels. Results were expressed as 
the mean ± SEM. *, Significant difference (P < 0.05); n = 4–7/group, where each n 
represents a single offspring derived from a different mother. 
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3.3.4 The LP2 induced reduction in hepatic Cyp7a1 protein in the 
male offspring is due to a decreased recruitment of RNA 
Polymerase II at the Cyp7a1 initiation site throughout fetal 
and postnatal development 
To explore the effects of LP2 on transcriptional mechanisms, chromatin 
immunoprecipitation (ChIP) was employed to examine the recruitment of RNA 
Polymerase II to the Cyp7a1 initiation site. Quantitative real-time PCR was used to 
amplify an approximate 100 bp genomic region surrounding the TATA box and the 
initiation site (Figure 3.5A,C,E,G).  This region was demonstrated to have maximal 
enrichment of RNA Polymerase II compared to distal sites of the Cyp7a1 promoter 
(Figure 3.6). At embryonic day 19, it was observed that there was a significant decrease 
in the recruitment of RNA Polymerase II to the initiation site of hepatic Cyp7a1 in the 
low protein fetuses (Figure 3.5A). Moreover, the decreased binding of RNA Polymerase 
II to the Cyp7a1 promoter persisted in the LP2 derived male offspring at both day 21 and 
day 130 (Figure 3.5C,E). The decrease in recruitment of RNA polymerase II was specific 
to the Cyp7a1 promoter region given no significant alterations in its recruitment was 
observed at the promoter of Gapdh, a housekeeping gene (Figure 3.5B,D,F,H). ChIP 
performed using non immune IgG displayed negligible level of binding to either the 
Cyp7a1 and Gapdh promoter region. The decrease in the recruitment of RNA Polymerase 
to the promoter of Cyp7a1 in LP2 offspring corresponded with both the decrease in 
Cyp7a1 protein levels (Figure 3.4A,B,D) and augmented cholesterol (Figure 3.2A,B). 
Given that there were sex-specific differences in circulating cholesterol and Cyp7a1 
expression between males and females at day 130, the recruitment of RNA Polymerase II 
to the Cyp7a1 promoter was examined at that age for both sexes. Unlike the males, ChIP 
revealed no corresponding differences in RNA Polymerase II binding to the promoter of 
Cyp7a1 in the females at this age (Figure 3.5G). 
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Figure 3.5. The effect of the LP2 dietary regime on the in vivo RNA polymerase II (RNA 
Pol II) binding at the initiation site of hepatic Cyp7a1 (A, C, E, and G) and the initiation 
site of Gapdh gene (B, D, F, and H) in rat offspring at embryonic d 19 (e19), male rat 
offspring at postnatal d 21, male and female rat offspring at postnatal d 130, respectively. 
ChIP was carried out on snap-frozen liver tissues by immuneprecipitation with antibody 
specific for RNA polymerase II. Quantification analysis on the immunoprecipitated 
solubilized DNA was carried out by real-time PCR via use of primers specific for the 
initiation sites on the promoter regions of hepatic Cyp7a1 and Gapdh. The relative level 
of immunoprecipitated genomic DNA was normalized to the total genomic DNA. Results 
were expressed as the mean ± SEM.*, Significant difference (P < 0.05); n = 4– 6/group, 
where each n represents a single offspring derived from a different mother. 
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Figure 3.6. In vivo RNA Polymerase II recruitment at three sites upstream of the hepatic 
Cyp7a1 promoter by employing ChIP with use of primers encompassing -2000 bp, -
500bp and the TATAA box regions of a control male rat offspring at postnatal day 21. 
ChIP was carried out on snap frozen liver tissues by immuneprecipitation with antibody 
specific for RNA Polymerase II. Quantification analysis on the immunoprecipitated 
solubilzed DNA was carried out by real time PCR via use of primers specifically 
targeting the -2000 bp, -500 bp and the TATAA box regions on hepatic Cyp7a1. The 
relative level of immunoprecipitated genomic DNA was normalized to the total genomic 
DNA. Results were expressed as the mean ± SEM. 
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3.3.5 Decreased recruitment of RNA Polymerase II in the LP2 
dietary regime is associated with chromatin silencing of 
Cyp7a1 promoter region via posttranslational histone 
modifications 
It is well established that decreased acetylation and/or an increased methylation of 
histone H3 [K9,14] is associated with chromatin silencing and decreased RNA 
Polymerase II binding
25, 26
. Therefore, to investigate whether posttranslational histone 
modifications influenced chromatin remodeling and RNA polymerase II recruitment to 
the Cyp7a1 promoter during LP2, we employed ChIP utilizing antibodies directed against 
histone H3 methylation [K9] and/or acetylation [K9,14]. At embryonic day 19, an 
increase in the acetylation of histone H3 (Figure 3.7A), but no change in trimethylation 
(Figure 3.7B) was observed surrounding the active site of Cyp7a1 promoter. This was 
despite the fact that the protein levels of Cyp7a1 were slightly reduced (Figure 3.4A). 
However, a significant decrease in the acetylation along with an increase in the 
methylation of histone H3 [K9], was observed at the hepatic Cyp7a1 promoter derived 
from LP2 male offspring at both day 21 (Figure 3.5C,D) and day 130 (Figure 3.5E,F). At 
both ages in LP2 males, these epigenetic changes correspond exactly with the observed 
decreased recruitment of RNA Polymerase II in the Cyp7a1 promoter (Figure 3.5C,E), 
diminished expression of Cyp7a1 (Figure 3.4B,D), and the observed increases in 
circulating and hepatic cholesterol (Figure 3.2A,B,C). In contrast, no alterations the 
acetylation [K9,14] or methylation [K9] of histone H3 were observed at the hepatic 
promoter of Gapdh at this age (Figure 3.8). Interestingly, in day 130 females, where no 
differences in circulating cholesterol or Cyp7a1 expression were observed (Figure 3.2B, 
3.4E), there was also no corresponding changes in acetylation (Figure 3.7G) or 
methylation (Figure 3.7H) surrounding the active site of Cyp7a1. 
 Given that the methylation of histone H3 [K9] can be influenced by specific [K9] 
demethylases
26
, we next examined whether changes in their expression facilitated the 
increases in the trimethlyation of histone H3 [K9] associated in the LP2 males. We 
examined only the steady state mRNA levels of those [K9] demethylases (Jmjd2a, 
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Jmjd2b, Jmjd2c, Jmjd2d) that removed trimethyl groups from [K9] of histone H3
26
. Real-
time quantitative PCR revealed that significant decreases in the hepatic Jmjd2a mRNA 
were observed only at embryonic d19 in LP fetuses (Figure 3.9A). No significant changes 
in the hepatic mRNA levels of Jmjd2b and Jmjd2c were observed between diets at this 
age, although there was a trend for a decrease in their expression due to the LP diet 
(Figure. 3.9B,C). The steady-state mRNA level of all of these [K9] demethylases was the 
same at d 21 (Figure 3.9D,E,F) and undetectable at d 130 in the control and LP2 dietary 
regimes (data not shown). The hepatic Jmjd2d mRNA was low to undetectable at all ages 
examined. This LP diet-induced decrease in the fetal hepatic expression of this [K9] 
demethylase may initiate the hypermethylation of histone H3 surrounding the 
Cyp7a1promoter observed in LP2 offspring. 
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Figure 3.7: The effect of LP2 dietary regime on the in vivo level of acetylated histone H3 
[K9,14] (A, C, E, and G) and trimethylated histone H3 [K9] (B, D, F, and H) at the 
hepatic Cyp7a1 LXRE site in rat offspring at embryonic d 19 (e19), male rat offspring at 
postnatal d 21, male and female rat offspring at postnatal d 130, respectively. ChIP was 
carried out on snap-frozen liver tissues by immunoprecipitation with antibodies for 
acetylated histone H3 [K9,14] and trimethylated histone H3 [K9]. Quantification analysis 
on the immunoprecipitated solubilized DNA was carried out by real-time PCR via use of 
primers specific for the LXRE site on the promoter regions of hepatic Cyp7a1. The 
relative level of immunoprecipitated genomic DNA was normalized to the total genomic 
DNA. Results were expressed as the mean ± SEM.*, Significant difference (P < 0.05); n 
= 4–6/group, where each n represents an offspring derived from a different mother. RXR, 
Retinoid X receptor. 
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Figure 3.8:  The effect of LP2 dietary regime on the in vivo level of A. Acetylated 
histone H3 [K9,14] and B. Tri-methylated histone H3 [K9] at the hepatic Gapdh initiation 
site in male rat offspring at postnatal day 130, respectively. ChIP was carried out on snap 
frozen liver tissues by immuneprecipitation with antibodies for acetylated histone H3 
[K9,14] and trimethylated histone H3 [K9]. Quantification analysis on the 
immunoprecipitated solubilzed DNAwas carried out by real time PCR via use of primers 
specific for the initiation site on the promoter regions of hepatic Gapdh. The relative level 
of immunoprecipitated genomic DNA was normalized to the total genomic DNA. Results 
were expressed as the mean ± SEM.* = significant difference (p<0.05). n=4-6/group, 
where each n represents an offspring derived from a different mother. 
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3.3.6 Protein restoration during lactation (LP3 dietary regime) 
enhances the recruitment of LXR to the promoter of 
Cyp7a1 at postnatal day 21 
Given the important role of LXR in the transcriptional regulation of Cyp7a1, we next 
investigated whether hepatic LXR levels were altered in the low protein offspring by 
postnatal day 21, the earliest time point of cholesterol dysregulation and impaired 
Cyp7a1 expression. Intriguingly, in both LP2 and LP3 offspring, increases in total 
hepatic LXR protein levels (Figure 3.10A,B) were observed. We next employed ChIP 
to investigate the in vivo binding of LXR to the promoter of Cyp7a1 containing a well 
characterized LXRE site.  Despite an increase in total LXR, LP2 offspring did not 
exhibit any alterations in the binding of LXR to the promoter of Cyp7a1 at day 21 
(Figure 3.10C). However, when the low protein offspring received a 20% protein diet 
during lactation (LP3), LXR binding was enhanced (Figure 3.10D). This is in 
association with restored Cyp7a1 expression in this dietary cohort (Figure 3.4D). 
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Figure 3.9: Quantitative RT-PCR mRNA level analysis of Jmjd2a (A and D), Jmjd2b (B 
and E), and Jmjd2c (C and F) in the livers of rat offspring derived at embryonic d 19 
(e19) and male rat offspring at postnatal d 21, respectively. RNA was extracted and 
reverse transcribed for quantitative RT-PCR. mRNA level expression was assessed via 
Q-RT-PCR using primers specific for Jmjd2a, Jmjd2b, Jmjd2c, and Hprt. The relative 
levels of each mRNA transcript were normalized to that of the levels of each Hprt mRNA 
transcript. Results were expressed as the mean ± SEM. *, Significant difference (P < 
0.05); n = 4–9/group at embryonic d 19, where each n represents an offspring derived 
from two different mothers and n = 5–6/group at postnatal d 21, where each n represents 
an offspring derived from a different mother. 
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Figure 3.10: The effect of LP1/LP2 (A and C) and LP3 (B and D) dietary regime on 
hepatic LXR_ protein and binding levels to Cyp7a1 LXRE site in rat offspring at 
postnatal d 21. Relative hepatic LXRα protein levels were determined using Western blot 
analysis. Total protein was isolated and LXRα protein was detected on a Western blot 
using the LXRα primary antibody. The LXRα protein level was quantified using 
densitometry and normalized to that of β-actin protein levels. Relative hepatic LXR_ 
binding levels to Cyp7a1 LXRE site were determined using ChIP analysis. ChIP was 
carried out on snap-frozen liver tissues by immunoprecipitation with antibody specific for 
LXRα. Quantification analysis on the immunoprecipitated solubilized DNA was carried 
out by real-time PCR via use of primers specific for the LXRE site on the promoter 
regions of hepatic Cyp7a1. The relative level of immunoprecipitated genomic DNA was 
normalized to the total genomic DNA. Results were expressed as the mean ± SEM.*, 
Significant difference (P < 0.05); n = 4–7/group, where each n represents a single 
offspring derived from a different mother. RXR, Retinoid X receptor. 
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3.4 Discussion 
In this study we present evidence for the first time that a low protein diet during 
pregnancy and lactation led to hypercholesterolemia in both sexes at postnatal day 21, 
with augmented cholesterol persisting in the male offspring at day 130. This was found to 
coincide with transcriptional repression of Cyp7a1, governed in part due to changes in 
posttranslational histone modifications surrounding the Cyp7a1 promoter during 
postnatal life. Moreover, low protein diet-induced decreases in the steady-state levels of 
Jmjd2a mRNA in utero may mediate the increased trimethylation of histone H3 (lysine 9) 
associated with this promoter at postnatal day 21 and day 130. These identified epigenetic 
and transcriptional mechanisms help in further understanding the link between IUGR and 
long-term cholesterol dysregulation. Uncovering these molecular mechanisms is critical 
given 50% of metabolic syndrome-related diseases can be linked to adverse events in 
utero
10-12
. In identifying some of the epigenetic mechanisms underlying the in utero 
origins of hypercholesterolemia, this study helps identify early life dietary and/or drug 
intervention strategies to lower cholesterol and reduce the incidence of the metabolic 
syndrome. Such strategies could reduce the long-term use of cholesterol lowering drugs 
in adulthood. 
As expected from previous studies by others(14-17) and in our laboratory
16-19
, a low 
protein diet resulted in reduced fetal to placental weight, neonatal growth, and liver to 
body weight ratio by postnatal day 21. Furthermore, this decrease in body weight 
persisted to adulthood (day 130) in offspring derived from a low protein diet during 
pregnancy and lactation, with (e.g. LP2) or without (e.g. LP1) a restoration in maternal 
protein content after lactation. This compliments previous studies suggesting that a low 
protein diet in early development has long-term implications on the overall growth of 
rats
38
. The maternal protein restriction model of IUGR in rats is a relevant model to study 
the fetal origins of adult diseases given that amino acids play a critical role in fetal 
growth
43
. Moreover, given placental insufficiency in humans can produce protein 
deficiency in the fetus
44
, this model share features in common with human PI-IUGR.  The 
impaired body weight is due to the low protein content in the diet given that maternal 
food intake was similar in all dietary regimes. Interestingly, the liver to body weight ratio 
86 
 
 
of offspring was not significantly different at postnatal day 130 in any dietary regime, 
suggesting that the impaired liver growth is ultimately recovered by adulthood, even 
though deficiencies in body weight may still be apparent. 
As evident from their body weight at day 21, restoration of protein in the maternal diet at 
birth (e.g. LP3) resulted in complete catch-up growth in these offspring, with no changes 
in the liver to body weight ratio. Moreover, they also exhibited enhanced Cyp7a1 protein 
levels, contributing to the prevention of hypercholesterolemia. Given that during this 
period there is a high rate of replication, neogenesis, and apoptosis leading to extensive 
liver remodeling in the newborn
45
, it is not surprising that a restoration of protein in the 
maternal diet during this developmental window rescued hepatic growth and function. 
Other studies have implicated the neonatal period as a period of plasticity in liver 
development
23, 46
. Stoffers et al. have demonstrated that in IUGR rats derived from 
uterine-ligated dams, neonatal administration of Exendin-4 (a GLP-1 analog), prevents 
the development of hepatic oxidative stress and insulin resistance
23
. Further 
understanding the molecular mechanisms underlying this plasticity could lead to 
improved therapies designed to enhance hepatic growth and function long-term. 
A low protein diet during pregnancy and lactation (e.g. LP1/LP2) was associated with 
hypercholesterolemia (~4.5 mM) at postnatal day 21 in both sexes. At this age, hepatic 
Cyp7a1 expression in these offspring was reduced two thirds compared to control.  This 
is intriguing given that Cyp7a1 has been previously demonstrated to display maximal 
expression at postnatal day 21
47, 48
. A LP1/LP2-induced increase in circulating 
cholesterol by three weeks of age is of considerable interest with regards to the early 
development of cardiovascular disease. Interestingly, when a low protein diet was fed to 
nursing mothers fostering control diet offspring, circulating cholesterol levels was not 
significantly different, highlighting the importance of the in utero environment in the 
long-term regulation of cholesterol levels. In LP2 offspring at day 130, circulating and 
hepatic cholesterol was significantly higher (~30%) in the male LP2 offspring.  The 
decrease in Cyp7a1 is likely the major contributor to the observed 30% increase in 
hepatic cholesterol given that there was no difference in the protein levels of Hmg-CoA 
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reductase (involved in cholesterol synthesis) and the LDL receptor (involved in 
cholesterol flux). 
The augmented circulating and hepatic cholesterol observed in these LP2 offspring is 
similar to what is observed in Cyp7a1-deficient mice and in humans with a mutation in 
CYP7A1
49, 50
.   This elevation in baseline cholesterol in combination with other diet and 
lifestyle factors (i.e. high fat diet) could make these animals more susceptible to 
hypertension and cardiovascular disease. For example, LP2 female offspring that were 
fed a control diet higher in carbohydrates after lactation exhibited elevated systolic blood 
pressure at 1 year of age
40
. Although males were not examined in that study, it remains 
possible from our study that the augmented cholesterol from as early as three weeks 
could collectively contribute to a similar or worse phenotype.  Moreover, the combination 
of impaired glucose tolerance
38
, visceral obesity
36
, and augmented cholesterol in these 
LP2 offspring would lead towards the development of metabolic syndrome. 
It is interesting to note that while LP2 offspring had augmented cholesterol at day 130, 
neither LP1 or LP3 offspring exhibited this phenotype. This is likely due to the fact that a 
low protein environment during development results in adaptations that are better suited 
to a similar environment later on in life
51
. Therefore, when a switch is made to a 20% 
protein diet after liver development
52
 (e.g. LP2), the offspring become more susceptible 
to physiological disorders. It was surprising to find that the LP3 animals had normal 
circulating cholesterol in our study, given previous work which has demonstrated that 
rapid catch-up growth in humans is more tightly associated with components of the 
metabolic syndrome
53
.  The answer may be due to the differences in liver development 
and the duration of the low protein insult. Liver development in rodents and humans 
consists of embryonic cell specification, budding, and then differentiation
52
. In rodents, 
liver differentiation develops later in gestation with a large portion of it occurring in 
postnatal life. In contrast, liver differentiation in humans already occurs in early to mid-
gestation
52. Therefore, at birth the rat liver is ‘less’ mature and has greater plasticity than 
the human liver. This makes the rat liver more susceptible to further insult or recovery 
during that period of neonatal life. This plasticity in liver development is evident in the 
LP3 offspring whereby Cyp7a1 expression was restored at postnatal day 21 due to 
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increases in LXR activation.  This is in contrast to the LP2 offspring, which did not 
exhibit alterations in LXR binding to the Cyp7a1 promoter. Collectively, this would 
suggest that it is the difference in the duration of the dietary low protein insult (LP2 = 43 
days versus LP3 = 21 days) throughout the crucial stages of rat liver development that 
likely plays a greater role in long-term liver impairment than catch-up growth. 
Epigenetic mechanisms have been previously demonstrated to underlie developmental 
programming of gene transcription. However, investigation of the epigenetic mechanisms 
linking an in utero insult to the development of disease in postnatal life is limited
18, 19, 23, 
24
. Since a conserved CpG island is not found in the promoter region of the human and 
rodent Cyp7a1, it is more likely that posttranslational histone modifications may 
influence its long-term expression compared to DNA methylation. In the present study, 
significant decreases in the acetylation and increases in methylation of histone H3 [K9], 
promoting a repressive chromatin environment, was observed surrounding the hepatic 
Cyp7a1 promoter in LP2 male offspring at postnatal day 21. This persisted into adulthood 
(day 130), long after the switch to a control diet. The observed repressive chromatin 
environment correlated with decreased recruitment of RNA Polymerase II, diminished 
Cyp7a1 protein levels, and the observed increases in circulating cholesterol.  This is not 
surprising as trichostatin A (TSA), a histone deacetylase inhibitor, has been previously 
demonstrated to increase Cyp7a1 expression and cholesterol metabolism when 
administered in mice
54
. It is interesting to note that the significant increase in histone H3 
trimethylation at postnatal days 21 was preceded by a decrease in the expression of the 
lysine 9 demethylase Jmjd2a during fetal life. This suggests that an early loss of 
demethylation in the fetal liver, due to a low protein diet, may initiate the enhanced 
trimethylation of histone H3 observed in LP2 offspring. 
While an increase in the acetylation of histone H3 [K9,14] was observed surrounding the 
Cyp7a1 promoter at embryonic day 19, recruitment of RNA polymerase II to its promoter 
and Cyp7a1 protein levels were modestly reduced. Moreover, increases in the overall 
trimethylation of histone H3 (lysine 9) were not observed at this time in development. 
Therefore in fetal life, the decreased expression of Cyp7a1 is likely also due to 
transcriptional mechanisms. Recently, it was demonstrated that a low protein diet in mice 
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led to decreased expression of LXRα and certain downstream target genes at embryonic 
day 19.5 as a result of increased DNA methylation at LXRα promoter22. Therefore, the 
decrease in recruitment of RNA polymerase II to the Cyp7a1 promoter in the fetuses 
derived from a low protein diet could possibly be due to decreased recruitment of LXRα 
at the Cyp7a1 LXRE site. 
To date, very little is known about the links between malnutrition and epigenetic 
mechanisms during development, specifically with regards to the regulation of histone 
modifying enzymes. One study looking at fetal surfactant protein A (SP-A) expression 
demonstrated that lower oxygen tension in vitro can promote alterations in these enzymes 
leading to a repressive chromatin environment
55
. Given this low protein model leads to 
asymmetric IUGR
20
, and that this brain-sparing effect is associated with fetal hypoxia
56, 
57
, this could conceivably mediate the observed decrease in JmjD2a expression. As a 
result, this would lead to the observed hypermethylation and hypoacetylation surrounding 
the promoter of Cyp7a1 during development. 
Recent studies in animal models have suggested that perturbations to the maternal 
environment during pregnancy can lead to sex-specific, long-term consequences in 
postnatal life. For example, LP2 offspring exhibited insulin resistance
42
 and visceral 
obesity
36
 exclusively in the adult male offspring at postnatal day 130. In this study, 
circulating cholesterol increased while a concomitant decrease in Cyp7a1 protein levels 
and RNA Polymerase II recruitment was observed only in the adult male offspring at 
postnatal day 130. Furthermore, the male-specific silencing of Cyp7a1 expression 
observed at day 130 was governed, in part, due to male-specific repressive changes in 
posttranslational histone modifications surrounding the active site of the Cyp7a1 
promoter. Given cholesterol and Cyp7a1 expression are misregulated in both sexes at day 
21, but only in males at day 130, it is unlikely that imprinting is involved.  Instead, it is 
plausible that gender-specific hormonal differences after lactation may mediate these 
programmed effects. It has been postulated that sex steroids (e.g estrogen) may offer the 
female some protective effects against the development of these disease processes, 
including elevated blood pressure
58
. Evidence from this comes from the aromatase 
knockout (ArKO) mouse, which cannot synthesize endogenous estrogens due to 
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disruption of the Cyp19 gene
59
. ArKO females when challenged with a high cholesterol 
diet had higher circulating cholesterol and lower Cyp7a1 expression compared to wild-
type females and males of either genotype
59
, where estrogen replacement reversed the 
hepatic steatosis
60
. However, the stimulatory effects of synthesizing estrogen may be only 
part of the reason for the sexual dimorphism observed in LP2 offspring. Given that LP2 
males have suppressed levels of circulating testosterone compared to control males
42
, it is 
conceivable that the loss of this male sex steroid may also underlie the male-specific 
impairment of Cyp7a1 and cholesterol catabolism. Aside from sex steroids, another 
important difference in LP2 males and females in that study was circulating basal insulin 
concentrations. LP2 male offspring at postnatal day 130 have two-fold higher levels of 
circulating insulin
42
, which has been previously demonstrated to inhibit Cyp7a1 in both 
the rat hepatocytes and streptozotocin (STZ)-induced diabetic rats via decreases in the 
binding of the transcription factors FoxO1 and Smad3 to the promoter of Cyp7a1
61
. 
Moreover, studies have now established that these hormones can influence 
posttranslational histone modifications. For example,  the estrogen receptor has been 
demonstrated to bind to coregulators (i.e. CBP/p300, SRC-1, SRC-2) that enhance 
promoter-specific histone H3 acetylation leading to an active chromatin state surrounding 
the promoter regions of estrogen responsive genes
62-64
. Therefore in LP2 females, it is 
conceivable that their ‘histone code’ was altered at the promoter of Cyp7a1 via the 
actions of these hormones. 
In conclusion, our results demonstrate that low protein diet-induced IUGR leading to 
augmented cholesterol in postnatal life results from permanent epigenetic silencing of the 
hepatic Cyp7a1 promoter, via posttranslational histone modifications. Moreover, our 
study identifies the in utero environment as a novel risk factor for cholesterol 
dysregulation, and aids our understanding of why a prevalence of metabolic syndrome-
related diseases can be linked to adverse events in fetal life.  Given the plasticity of the 
liver in fetal and neonatal life, further studies will undoubtedly lead to early life dietary 
and/or drug intervention strategies to lower cholesterol and reduce the incidence of the 
metabolic syndrome in adulthood. 
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4 NUTRITIONAL MISMATCH IN POSTNATAL LIFE OF LOW 
BIRTH WEIGHT RAT OFFSPRING LEADS TO INCREASED 
PHOSPHORYLATION OF HEPATIC EUKARYOTIC INITIATION 
FACTOR 2 IN ADULTHOOD3 
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 The material in this chapter is based on a manuscript accepted (METABOLISM-D-13-00099): Sohi G, 
Revesz A, Hardy DB Nutritional Mismatch in Postnatal Life of Low Birth Weight Rat Offspring Leads to 
Increase Phosphorylation of Hepatic Eukaryotic Initiation Factor 2  in Adulthood.(2013) 
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4.1 Introduction 
Adverse events during development can be linked to an increased risk for developing 
obesity, cardiovascular disease (CVD) and diabetes. The “Predictive Adaptive Response” 
hypothesis suggests that these adverse events would induce fetal adaptations that result in 
a “survivor phenotype” which is advantageous in a similar predictive future reproductive 
environment
1. However, if there is a ‘mismatch’ to this predictive environment, these 
adaptations would lead to a “thrifty phenotype” which is maladaptive2, 3. Clinically, 
preterm infants that exhibited catch-up growth due to higher nutrient exposure have 
increased markers of the metabolic syndrome by adolescence
4-8
. Similarly, in 
experimental rodent models leading to low birth weight, accelerated postnatal growth 
rates due to overfeeding is associated with hypertension
9
, obesity
10
, 
hypercholesterolemia
11
, insulin resistance
10
 and reduced longevity
12
While the link 
between impaired fetal growth and the risk for developing chronic disease in adulthood is 
undoubtedly strong, the underlying mechanisms are still being elucidated.  Some of these 
mechanisms include epigenetics, alterations in transcription factor (i.e. nuclear receptors) 
activity, mitochondrial dysfunction and impaired organogenesis
13, 14
 
  Another mechanism underlying the development of the metabolic syndrome in low 
birth weight offspring may be due to impairment of protein synthesis. Protein synthesis is 
considered critical for normal growth and has been associated with risk factors that 
contribute to onset of metabolic diseases.  For example, obese male subjects complicated 
with type 2 diabetes have lower rates of whole-body protein synthesis
15
. Moreover, 
guinea pigs with hypercholesterolemia exhibit decreased protein synthesis in the heart, 
brain, kidney and liver
16
. In metazoans, protein translation is known to be negatively 
regulated at the initiation stage by increases in the phosphorylation of eukaryotic 
initiation factor (eIF)-2 at Serine (Ser) 51 residue17, 18. Interestingly, in vitro studies 
provide robust evidence for an inverse correlation between phosphorylation of eIF2 
(Ser51) and phosphorylation of Akt1 (Ser473), a marker of insulin sensitivity
19-22
. To 
address this relationship in the context of insulin signaling, a study by Achard and Labutt 
using HepG2 human hepatoma cells demonstrated that palmitate treatment increased 
phospho-eIF2α (Ser51) within 1 hour and decreased phospho-Akt1 (Ser473) in response 
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to insulin simulation 18 hours later
22
. Yet, the link between phosphorylation of eIF2 to 
phosphorylation of Akt1 (Serine 473) has not been fully examined in a physiological 
context (i.e. maternal nutrition) in vivo. Moreover, little is known about how a nutritional 
mismatch between fetal and neonatal life would influence these two established markers 
of protein translation and insulin resistance.  
 The maternal protein restriction (MPR) rat model has been extensively studied to 
support the “predictive adaptive response” hypothesis. For instance, low birth weight 
offspring derived from MPR have a reduced lifespan when recuperated under a normal 
protein diet at birth or after weaning
23, 24
. On the other hand, in the absence of protein 
restoration, rat offspring tend to live longer
24
. A reduction in longevity can be attributed 
to an earlier onset of metabolic risk factors in these intrauterine growth restricted (IUGR) 
offspring, including insulin resistance
25-28
. Our laboratory and others have previously 
observed impaired liver function to be associated with elevated hepatic cholesterol, 
glucose and oxidative stress in MPR offspring
25, 29, 30
. Given that impaired liver function 
is a key contributor to the etiology of the metabolic syndrome, we chose to examine 
whether these MPR offspring receiving nutritional mismatch exhibit increases in hepatic 
phosphorylation of eIF2 (Ser51) in postnatal life. In addition, we sought to determine 
whether this corresponded with decreases in phosphorylation of Akt1 (Ser473) in vivo. 
Moreover, given that the phosphorylation of eIf2 (Ser51) is also increased in response 
to endoplasmic reticulum (ER) stress, which is associated with the metabolic syndrome
31-
33
, we aimed to measure markers of hepatic ER stress (Glucose regulated protein 78/94 
and spliced Xbp1) in these MPR offspring. To address these questions, three separate 
dietary regimes were employed in pregnant rats. These include a normal (20%) protein 
diet administered throughout life (control), a low (8%) protein diet throughout life (LP1), 
until weaning (LP2), or exclusively prenatally  (LP3). 
4.2 Materials and Methods 
4.2.1 Animals and Dietary Regimes 
All procedures were performed in accordance with the guidelines set by the Canadian 
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Council of Animal Care and upon approval of the Animal Care Committee of the 
University of Western Ontario. Female and male Wistar rats at breeding age (250 g; 8-10 
weeks old) were purchased from Charles River (La Salle, St. Constant, Quebec, Canada). 
These rats were housed in individual cages and maintained at room temperature on a 12-h 
light, 12-h dark cycle. For 3 weeks, these rats were left to acclimatize to the animal care 
facility, and their reproductive cycles were followed. At the onset of proestrus, these rats 
were mated. Impregnation was confirmed by the presence of sperm in the vaginal smear 
the next morning. Upon confirmation of impregnation (gestation day 1), the rats were fed 
either a control diet containing 20% protein (Bio-Serv, Frenchtown, NJ, USA, Product# 
F4576 – Rodent Diet, AIN-93G, Blue, ½” pellets) or a LP diet containing 8% protein 
(Bio-Serv, Frenchtown, NJ, USA, Product#F4575 – Rodent Diet, AIN-93G, ½” pellets). 
The LP diet contained similar fat content and was made isocaloric (3.61 kcal/gram for 
control and 3.66 kcal/gram for LP diet) by the addition of carbohydrates (Bio-Serv, 
Frenchtown, NJ, USA). At birth, the litter size was reduced to 8 animals (4 females and 4 
males), with weights closest to the litter mean. This ensured a standard litter size for all 
mothers and no overnutrition. Three different dietary regimes were administered to these 
offspring (Figure 4.1A). Offspring derived from a maternal LP diet were either 
administered the LP diet throughout postnatal life (LP1), until the end of weaning (LP2), 
or exclusively prenatally  (LP3). Food and water was provided ad libitum, and food 
intake was recorded during pregnancy and in the offspring. For consistency, only male 
offspring were used for the study because early-life programming is known to occur in a 
sexually dimorphic manner
34
, which was not the focus of this study. At embryonic day 19 
(e19), 16 pregnant rats (8 control and 8 low protein diet pregnancies) were sacrificed and 
the fetal livers were excised and snap frozen for immunoblot analysis. Another subset of 
24 rats (8 control and 16 low protein diet pregnancies) were allowed to deliver 
spontaneously. The food intake of these offspring were monitored by measuring their 
food consumption every third day, and have been previously published
25
. At postnatal 
day 130 (d130), 8 pups, each representing a single offspring from a different mother, 
were sacrificed per dietary regime (control, LP1, LP2 and LP3) and the medial lobe liver 
tissue was excised and frozen for quantitative RT-PCR and immunoblot analysis. 
102 
 
 
4.2.2 Postnatal Growth Rate Analysis 
From parturition to postnatal day 130, offspring body weights were recorded daily.  The 
growth curves for the four dietary regimes were obtained by plotting average body 
weight (grams) ± the SEM against time (days). The growth curves displayed a best fit to 
a sigmoidal curve with variable slope. Therefore, the data sets were analyzed under non-
linear regression using GraphPad Prism 5. The steepness of the curve was determined 
by the slope factor value, which in this study reflected growth rate of the offspring. 
4.2.3 Real Time PCR Analysis 
Total RNA from Wistar rat medial lobe liver tissue was extracted at e19 and postnatal 
d130 by the one-step method of Chomczynski and Sacchi (Trizol, Invitrogen, Carlsbad, 
CA)
 226
. RNA was treated with deoxyribonuclease to remove any contaminating DNA. Of 
the total RNA, 4g were reverse transcribed to cDNA using random primers and 
Superscript II RNase H-reverse transcriptase (Invitrogen). Primer sets directed against 
total rat Xbp-1 forward (5’-CTCAGAGGCAGAGTCCAAGG-3’) and reverse (5’-
CTCTGGGGA-AGGACATTTGA-3’) and -actin forward (5’-
ACGAGGCCCAGAGCAAGA-3’) and reverse (5’-TTGGTTACAATGCCGTGTTCA-
3’) were generated via Primer Express software (PE Applied Biosystems, Boston, MA, 
USA). The relative abundance of each transcript was determined by real-time quantitative 
PCR as previously published
25
. For the quantitative analysis of mRNA expression, the 
Bio-Rad CFX384 Real Time System was employed using the DNA binding dye IQ 
SYBER green supermix (Bio-Rad, Mississauga, Ontario, Canada). The cycling 
conditions were 50C for 2 min, 95C for 10 min, followed by 40 cycles of 95C for 15 
sec, and 60C for 1 min. The cycle threshold was set at a level where the exponential 
increase in PCR amplification was approximately parallel between all samples. All 
primer sets produced amplicons of the expected size and sequence. We calculated the 
relative fold changes using the comparative cycle times (Ct) method with -actin as the 
reference guide. Over a wide range of known cDNA concentrations, all primer sets were 
demonstrated to have good linear correlation (slope=-3.4) and equal priming efficiency 
for the different dilutions compared with their Ct values (data not shown). Given that all 
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primer sets had equal priming efficiency, the Ct values (primer internal control) for each 
primer set were calibrated to the experimental samples with the lowest transcript 
abundance (highest Ct value). The relative abundance of each primer set compared with 
calibrator was determined by the formula, 2
Ct
, in which Ct is the calibrated Ct 
value. 
4.2.4 Quantitative Real Time PCR Analysis of Xbp-1 spliced 
mRNA Levels 
This assay was performed using modifications of previously published methods
25, 35
. 
Briefly, 4g of RNA reverse transcribed to cDNA was added to a tube of 3.5 mM MgCl2, 
0.12 mM each of dNTP (A, T, G, C), 1 x PCR reaction buffer (-MgCl2) (Invitrogen), 0.15 
M rat Xbp-1 primer forward (5’-GCTTGTGATTGAGAACCAGG-3’) and reverse 
(5’AGGCTTGGTGTATACATGG-3’), 0.05 units/L Taq DNA Polymerase, Native 
(Invitrogen). The mixture was incubate at 50C for 2min, 95C for 10 min, followed by 2 
cycles of 95C for 15 sec, and 60C for 1 min. 2.25 units//L Pst1 restriction enzyme 
(Invitrogen) was added to the reaction mixture for 2 hours to digest the double stranded 
cDNA of unspliced Xbp-1. The remaining mixture containing the spliced Xbp1 cDNA 
was used towards determining Xbp1-spliced mRNA levels via quantitative real-time PCR 
analysis. 
4.2.5 Preparation of Tissue Total Protein Extracts and Immunoblot 
Analysis  
Frozen Wistar rat liver tissue were homogenized in RIPA buffer (50 mM Tris-HCl, pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, 0.25% C24H39NaO4, supplemented 
with 1mM NaV, 50mM NaF and 25mM C3H7O6PNa2.XH2O), and protease inhibitor 
cocktail (Roche). The homogenate was sonicated using five pulses of 1 second each with 
amplitude of 30 % (Misonix Sonicator 4000, Newtown, CT, USA). Following sonication, 
the homegenate was centrifuged at 300 g for 15 min at 4C. The supernatant was retained 
and centrifuged at 14000 rpm for 20 min at 4C. The supernatant was retained as the total 
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cellular protein fraction. Equal concentrations of proteins normalized by colorimetric 
BCA Protein Assay (Pierce Corp., Madison, WI, USA), were fractionated in gradient 
polyacrylamide gels (Invitrogen) and transferred onto polyvinylidenedifluoride 
membrane (Millipore). Blots were probed using p-eIF2α (S51) rabbit monoclonal 
antibody (1:1000, Cell Signaling Technology, Danvers, MA, USA), eIF2α rabbit 
polyclonal antibody (1:1000, Cell Signaling), p-Akt1 (S373) rabbit polyclonal antibody 
(1:1000, Abcam Inc., Cambridge, MA), Akt-1 rabbit polyclonal antibody (1:1250, 
Abcam), Kdel ER marker mouse monoclonal antibody (1:200, Santa Cruz Biotechnology 
Inc., Santa Cruz, CA), and monoclonal horseradish peroxidase-conjugated -actin 
(1:50000, Sigma-Aldrich Oakville, Ontario, Canada) diluted in 5% milk-1Tris-buffered 
saline-Tween 20 buffer. Horseradish peroxidase-conjugated donkey antirabbit IgG 
(1:10000, Jackson ImmunoResearch Laboratories, West Grove, PA) or horseradish 
peroxidase-conjugated donkey antimouse IgG (1:5000, Jackson ImmunoResearch 
Laboratories) diluted in 5% milk 1Tris-buffered saline-Tween 20 buffer were used as 
the secondary antibodies, respectively. Immunoreactive bands were visualized using an 
enhanced chemiluminescence detection system (Thermo Scientific, Waltham, MA, 
USA).  
4.2.6 Statistics 
All results were expressed as the mean of arbitrary values ± the SEM. The significance of 
differences (P  0.05) between mean values was evaluated using the unpaired Student’s t 
test for results from growth profile data, quantitative RT-PCR, and immunoblot analysis.  
4.3 Results 
4.3.1 Overall Growth Rates are Greater for MPR Offspring Derived 
from a Low Protein Diet Until Birth (LP3) or Weaning (LP2)  
Offspring derived from all four dietary regimes (C, LP1-3) had a growth curve pattern 
that matched a sigmoidal curve with variable slope and displayed an R
2
 value of 0.99 
(Figure 4.1C).  Maternal low protein diet derived low birth weight offspring which were 
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recuperated under a normal protein diet until birth (LP3) or weaning (LP2) had a higher 
overall growth rate when compared to those maintained on a low protein diet throughout 
life (LP1) (Figure 4.1B). The overall growth rates were inferred by the slope factor values 
(Figure 4.1C). When compared to the Control group, the growth rates of LP2 offspring 
were significantly higher (p<0.05) and LP1 were significantly lower (p<0.01, Figure 
4.1C). Interestingly, the overall growth rates of LP3 were identical to that of the Control 
group, despite the fact that LP3 offspring were born low birth weight (Figure 4.1B, C). 
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Figure 4.1: The effect of maternal protein restricted (MPR) dietary regimes on 
growth profile in wistar rats. The growth profile was examined for A. the four separate 
dietary regimes which include a normal (20%) protein diet administered throughout life 
(Control) and a low (8%) protein diet administered throughout life (LP1), until weaning 
(LP2) or exclusively prenatally (LP3), B. the body weight (grams) were plotted against 
days in postnatal life and C. the slope factor value were determined under a non-linear 
regression (non fit curve) by setting line of best fit to a sigmoidal curve with a variable 
slope in GraphPad Prism 5. Results were expressed as the mean ± SEM. *, Significant 
difference (P <0.05) compared to the Control group; n=14-22/group, where each n 
represents a single offspring derived from a different mother. 
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4.3.2 Offspring derived from a low protein diet until birth (LP3) or 
weaning (LP2) exhibit increased phosphorylation of hepatic 
eIF2α (Ser51) by postnatal day 130. 
In this study, we observed that hepatic protein translation was inhibited exclusively in the 
livers of adult maternal low protein diet derived IUGR offspring who recuperated under a 
normal protein diet in postnatal life. These included offspring derived from a LP2 and 
LP3 dietary regime, where significant increases in phosphorylation of eIF2 (Ser51) 
were observed in the livers at postnatal day 130 compared to Control (Figure 4.2B, C). 
Interestingly, in IUGR offspring subjected to protein restriction throughout pregnancy 
and postnatal life (LP1), a significant decrease in phosphorylation of eIF2 (Ser51) was 
observed in the livers at postnatal day 130 compared to Control (Figure 4.2A). In 
addition, the phosphorylation levels of eIF2 (Ser51) inversely correlated with 
phosphorylation levels of Akt1 (Ser473) with respect to LP1 and LP2 offspring (Figure 
4.2A, B). This correlation was absent at postnatal day 130 in the LP3 offspring (Figure 
4.2C). 
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Figure 4.2: The effect of MPR dietary regimes on hepatic phosphorylated eIF2α 
(Ser51) protein levels at d130. The effect of A. LP1, B. LP2 and C. LP3 dietary regimes 
on phosphorylated protein kinase B (Akt1) at Serine 473, Akt1, eukaryotic initiation 
factor 2 α (eIF2α) at Serine 51 and eIF2α protein levels in the livers of male offspring at 
postnatal day 130. Relative p-Akt1 (S473), Akt1, p-eIf2α (S51) and eIf2α protein levels 
were determined using Western blot analysis. Total protein was isolated and p-Akt1 
(S473), Akt1, p-eIF2α (S51) and eIF2α protein were detected on a Western blot using p-
Akt1 (S473), Akt1, p-eIF2α (S51) and eIF2α primary antibody. Their protein levels were 
quantified using densitometry and normalized to that of -actin protein levels. Results 
were expressed as the mean ± SEM. *, Significant difference (P <0.05); n=5–7/group, 
where each n represents a single offspring derived from a different mother. 
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4.3.3 Phosphorylation of eIF2 (Ser51) protein levels were 
unaltered by maternal protein restriction in the fetal livers at 
embryonic day 19 
Since an increase in phosphorylation of eIF2 (Ser51) was observed by adulthood in 
MPR offspring that received a Control protein diet postpartum (LP3) or post-weaning 
(LP2), we further pursued whether hepatic protein translation attenuation was exclusive 
to adult life or was persistent from fetal life. At embryonic day 19, there were no changes 
phosphorylated eIF2 (Ser51) protein levels (Figure 4.3). Moreover, hepatic phospho-
Akt1 (Ser473) protein levels were also normal compared to the Control (Figure 4.3).  
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Figure 4.3: The effect of MPR on phosphorylated eIF2α (Ser51) protein levels in 
fetal livers at embryonic d19. The effect of maternal low protein diet on phosphorylated 
protein kinase B (Akt1) at Serine 473, Akt1, eukaryotic initiation factor 2 α (eIF2α) at 
Serine 51 and eIF2α protein levels in the fetal livers at embryonic day 19. Relative p-
Akt1 (S473), Akt1, p-eIf2α (S51) and eIf2α protein levels were determined using 
Western blot analysis. Total protein was isolated and p-Akt1 (S473), Akt1, p-eIF2α (S51) 
and eIF2α protein were detected on a Western blot using p-Akt1 (S473), Akt1, p-eIF2α 
(S51) and eIF2α primary antibody. Their protein levels were quantified using 
densitometry and normalized to that of -actin protein levels. Results were expressed as 
the mean ± SEM. *, Significant difference (P <0.05); n=7/group, where each n represents 
a single offspring derived from a different mother. 
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4.3.4 Elevated ER chaperones in the livers of adult offspring 
derived from a LP diet exclusively during pregnancy (LP3) 
and during pregnancy and lactation (LP2)  
Another marker indicating that the perinatal environment may lead to ER stress in 
adulthood is through an increase in ER chaperone proteins. Adult offspring derived from 
a LP diet exclusively during pregnancy (LP3) and during pregnancy and lactation (LP2) 
resulted in elevated hepatic ER chaperones by postnatal day 130 (Figure 4.4B, C). 
Specifically, there was a significant increase in ER chaperones Grp78 in the LP2 derived 
offspring, and Grp94 in the LP3 derived offspring in adulthood compared to Control 
(Figure 4.4B, C). Interestingly, LP1 derived offspring displayed no changes to ER 
chaperone Grp94 and 78 protein levels (Figure 4.4A). 
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Figure 4.4: The effect of MPR dietary regimes on hepatic ER chaperones protein 
levels at d130. The effect of A. LP1, B. LP2 and C. LP3 dietary regimes on Glucose 
regulatory protein 94 and 78 (Grp94 & Grp78) protein levels in the livers of male 
offspring at postnatal day 130. Relative Grp94 and Grp78 protein levels were determined 
using Western blot analysis. Total protein was isolated and Grp94 and Grp78 protein 
were detected on a Western blot using KDEL primary antibody, which recognizes the 
carboxyl terminus KDEL sequence of Grp94 and Grp78. Their protein levels were 
quantified using densitometry and normalized to that of -actin protein levels. Results 
were expressed as the mean ± SEM. *, Significant difference (P <0.05); n=5–7/group, 
where each n represents a single offspring derived from a different mother. 
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4.3.5 Increases in Xbp-1 spliced variant mRNA levels coincide 
with the elevated ER chaperone protein levels and enhanced 
phosphorylation of eIF2α (Ser51) in the livers of adult 
offspring derived from LP2 and LP3 dietary regimes 
The spliced variant Xbp-1 is a more potent form of Xbp-1 transcription factor which 
activates a wide variety of genes involved with ER stress activation pathway, including 
ER chaperone proteins
36, 37
. In this study, we observed an increase in spliced variant Xbp-
1 mRNA levels in the livers of LP2 and LP3 derived offspring in adulthood compared to 
Control (Figure 4.5B, C). The increase in spliced Xbp-1 mRNA levels partially correlated 
with the increase in protein levels of spliced Xbp-1 downstream transcriptional targets, 
the ER chaperone proteins (Figure 4.4B, C). Moreover, spliced Xbp-1 mRNA levels in 
the livers of LP1 derived offspring were unchanged, which correlates with no change to 
ER chaperones Grp94 and 78 in these offspring (Figure 4.4A). 
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Figure 4.5: The effect of MPR dietary regimes on hepatic Xbp-1 spliced variant 
mRNA levels at d130. The effect of A. LP1, B. LP2 and C. LP3 dietary regimes on X-
box binding protein (Xbp-1) spliced variant mRNA levels in the livers of male offspring 
at postnatal day 130 via quantitative RT-PCR analysis. RNA was extracted and reverse 
transcribed for quantitative RT-PCR using primer specific for Xbp-1. Reverse transcribed 
RNA was first amplified by Taq DNA Polymerase for two PCR cycles and then treated 
with Pst1 restriction enzyme to allow for splicing of all unspliced Xbp-1 transcripts. 
Quantitative RT-PCR was then performed to amplify exclusively the Xbp-1 spliced 
transcript. The relative levels of each Xbp-1 spliced mRNA transcript were normalized to 
that of the levels of each β-actin mRNA transcript. Results were expressed as the mean ± 
SEM. *, Significant difference (P <0.05); n=7/group, where each n represents a single 
offspring derived from a different mother. 
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4.4 Discussion 
In this study, we demonstrated that there is an increase in phospho-eIF2 (Ser51) in the 
adult livers of IUGR rat offspring exclusively when they undergo accelerated growth 
rates as a consequence of a nutritional protein mismatch. Moreover, when there is no 
mismatch between fetal and postnatal nutrition, the IUGR offspring experience slower 
growth rates and do not exhibit hepatic protein translation attenuation in adult life. This 
further supports the central tenet of the ‘thrifty phenotype’ hypothesis that long-term 
adverse metabolic effects are most apparent when there is a mismatch between early 
nutritional deprivation and later nutritional affluence
2, 3, 38
. Collectively, this study helps 
to identify appropriate dietary intervention strategies for reducing the incidence of the 
metabolic syndrome in IUGR offspring by highlighting the beneficial effects of matching 
the prenatal and postnatal environment to maintain protein translation in the liver. It is 
conceivable that such strategies could reduce the long-term usage of drugs prescribed to 
manage symptoms of the metabolic syndrome. 
MPR derived IUGR offspring that recuperated under a normal protein diet post-weaning 
(LP2) or postpartum (LP3) displayed accelerated growth rates compared to MPR 
offspring maintained on a low protein diet throughout fetal and postnatal life (LP1). 
These accelerated growth rates  (i.e. those exhibited by LP2 and LP3 offspring) mirrored 
decreases in hepatic protein translation as reflected through increases in phospho-eIF2 
(Ser51) levels. Conversely, slower growth rates due to an absence of a nutritional 
mismatch (e.g. LP1) resulted in a decrease in phospho-eIF2 (Ser51) in adulthood. Since 
no change was observed in the levels of hepatic phospho-eIF2 (Ser51) at embryonic day 
19, accelerated growth rates is likely the more significant contributing factor to protein 
translation attenuation in adult life, as opposed to the direct actions of the low protein diet 
itself during pregnancy. However, to provide further support for the “predictive adaptive 
response” hypothesis, it would be of interest to investigate the effects of low protein diet 
exclusively administered during lactation or post-lactation.  Our previous studies have 
suggested that a low protein diet exclusively in fetal life or during pregnancy and 
lactation did not alter circulating cholesterol
25
, indicating that a longer fetal and neonatal 
low protein insult is necessary for impaired hepatic function long-term. Interestingly, four 
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serine/threonine protein kinases have been identified to phosphorylate eIF2. These 
include general control nonrepressed 2 kinase (GCN2), heme-regulated inhibitor kinase 
(HRI), double stranded RNA-activated kinase (PKR) and protein kinase RNA-like 
endoplasmic reticulum kinase (PERK) which are activated by amino acid depletion, 
hypoxia, viral infection and accumulation of misfolded proteins, respectively
17, 18
. 
However, this study did not investigate whether these kinases were involved in increasing 
levels of phospho-eIF2 (Ser51) observed in LP2 and LP3 offspring. Moreover, other 
stages of protein synthesis regulation by important amino acid sensing modulators such 
as through the mammalian target of rapamycin kinase (mTOR) were also not examined 
but deserve consideration
19
. 
 Intriguingly, the LP2 and LP3 offspring display an accelerated growth rate despite 
the observed increase in hepatic phospho-eIF2 (Ser51), an indicator of reduced protein 
translation. The changes in growth occurred in spite of the fact that food intake was not 
different between dietary groups
25
. Rather, this might be explained by changes in 
adiposity since visceral fat mass and the fat to body weight ratio have been reported to be 
twice as high in these LP2 offspring relative to the control
26, 27
. Therefore, it is plausible 
that an increase in visceral obesity may predominantly underlie the increases in 
accelerated growth (as assessed by bodyweight) in the LP2 and LP3 offspring, even 
though the overall protein synthesis may be reduced in the liver. Interestingly, a decrease 
in whole body protein synthesis has been previously reported in male type 2 diabetic 
patients with obesity
15
. It is also noteworthy that even though the low birth weight LP2 
offspring have a higher slope factor, reflecting higher overall growth rate, they do not 
fully catch-up in size to the normal birth weight control offspring as they reach their 
growth plateau sooner. With respect to the impact of phospho-eIF2 and on liver growth, 
it is noteworthy the liver:body weight ratio was reduced 50% in LP offspring at 
embryonic day 19 (when phospho-eIF2 was unchanged), they were caught up by day 
130
25
. This suggests that the observed increases in phospho-eIF2 in LP2 and LP3 
offspring at postnatal day 130 may occur after the liver has undergone differentiation and 
growth. 
An inability to induce protein translation is likely due to decreased insulin sensitivity in 
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the liver
34
. In this study we observed an increase in phospho-Akt1 (Ser473) to be 
associated with a decrease in phospho-eIF2 (Ser51) in LP1 offspring. Conversely, a 
decrease in phospho-Akt1 (Ser473) was observed to be associated with an increase in 
phospho-eIF2 (Ser51) in the LP2 offspring. This finding confirms previous in vitro 
studies which have observed a bi-directional association between phosphorylated eIF2 
(Ser51) and phosphorylated Akt1 (Ser473) by administering pharmacological inhibitors 
of Akt1 and eIF219-22. Despite elevated phospho-eIF2 (Ser51) levels, the LP3 
offspring did not display corresponding decreases in phospho-Akt1 (Ser473). This may 
be due to the fact that some of the adverse effects of a low protein diet are rescued by 
protein restoration during the first three weeks of neonatal life, a period of plasticity in 
the developing rat liver
46
. It can be postulated that this correlation may eventually hold 
true in the LP3 offspring later on in life provided phospho-eIF2 (Ser51) remain elevated 
past day 130. Collectively, these results support the notion that elevated phospho-eIF2 
(Ser51) could be contributing to a reduction in hepatic insulin sensitivity in LP2 and LP3 
derived adult offspring. Interestingly, LP2 offspring have been previously demonstrated 
to exhibit increases in HOMA-IR, glucose intolerance and decreases in hepatic 
glucokinase activity
27, 39
. Alternatively, it remains to be determined whether a decrease in 
phospho-eIF2 (Ser51) and slower growth rates in LP1 IUGR offspring is beneficial to 
increasing hepatic glucokinase activity, insulin sensitivity, and glucose tolerance. It is 
noteworthy that these LP1 offspring do live longer
24
.   
Interestingly, protein translation attenuation via increases in phospho-eIF2 (Ser51) is 
also one of the hallmark responses of elevated ER stress. ER stress is a result of excessive 
accumulation of misfolded or unfolded proteins in the ER lumen due to a variety of 
environmental insults
40
. The accumulation of these proteins triggers the activation of the 
ER stress pathway, which is also referred to as the unfolded protein response (UPR)
40
. 
UPR aims to alleviate ER stress by decreasing global protein translation in order to 
reduce the load of the ER in processing these new proteins. In addition to a reduction of 
global protein translation, there is also an increase in ER chaperone protein levels (i.e. 
glucose regulated protein Grp78 and Grp94) to improve ER’s protein folding capacity36, 
37
. Furthermore, ER stress induces the splicing of a highly conserved unconventional 26 
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bp intron of the X-box binding protein 1 (Xbp-1) mRNA, which encodes for a potent 
transcription factor involved with transcriptional upregulation of genes involved with 
coping with the ER stress
36, 37
. Collectively, an increase in phosphorylation of eIF2 
(Serine 51), Grp94 and Grp78 protein levels, and splice variant XBP-1 mRNA level are 
considered hallmark indicators of elevated ER stress. Given the critical role of 
endoplasmic reticulum in overall cellular functions and survival, any stress to the ER 
would therefore aggravate the symptoms associated with the metabolic syndrome. We 
were interested in measuring these markers of UPR given ER stress has been 
demonstrated to lead to aspects of the metabolic syndrome (insulin resistance, obesity 
and hypercholesterolemia)
31-33, 41
 which are also exhibited in MPR offspring
25-27
. In 
addition to increases in phospho-eIF2α (Ser51) in the adult livers of LP2 and LP3 
offspring, we also observed increases in Xbp-1 splice variant mRNA levels. Since splice 
variant Xbp-1 transcription factor is known to upregulate the transcription of ER 
chaperones
36, 37
, we expected corresponding increases in ER chaperones Grp78 and 
Grp94 protein levels. However, in both LP2 and LP3 only one of the two ER chaperone 
protein levels were significantly elevated. It is still noteworthy that the ER chaperone 
Grp78, a downstream target gene of spliced Xbp-1, has been demonstrated to prevent an 
increase in phospho-Akt1 (Ser473)
42
. Therefore the increase in hepatic spliced Xbp1 
mRNA and Grp78 protein levels in the LP2 offspring may also help explain for our 
observed decreases in hepatic phospho-Akt1 (Ser473) and the reported insulin resistance 
in these offspring
27
. 
In summary, we provide evidence that in addition to epigenetic and transcriptional 
mechanisms underlying the ‘developmental origins of adult disease’, protein translation 
attenuation may mediate long-term insulin resistance and other aspects of the metabolic 
syndrome. Confirming the main tenets of the ‘thrifty hypothesis’, our results also 
demonstrated that only in the situation whereby MPR offspring were faced with a protein 
dietary mismatch from fetal to postnatal life did they display reduced hepatic protein 
translation in adulthood. Moreover, these offspring were more susceptible to developing 
insulin resistance and other markers of the metabolic syndrome as they displayed 
indicators of elevated ER stress. The management of early life diet to reduce accelerated 
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postnatal growth and improve hepatic protein synthesis in IUGR offspring may prove to 
be an important intervention strategy to decrease the incidence of the metabolic syndrome 
in adulthood. 
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5.1 Introduction 
Clinical studies have reported a strong correlation between low birth weight and 
metabolic risk factors associated with cardiovascular disease (CVD)
1-5
. Therefore, the 
likelihood of prescribing medication for the management of these metabolic symptoms 
(e.g. statins for hypercholesterolemia) can be considered to be greater in these offspring. 
This may be particularly relevant in cases of low birth weight offspring, which undergo 
nutrition-induced accelerated growth in neonatal life and display an earlier onset of these 
symptoms
6-11
. The underlying reason behind this phenomenon can be explained by the 
“Predictive Adaptive Response” hypothesis, which suggests that adverse events during 
development induce adaptations suited for survival in a similar predictive environment 
but can become maladaptive if a ‘mismatch’ to the predictive environment occurs, 
leading to a “thrifty phenotype”12-14. Clinically, this hypothesis has been supported by 
evidence where accelerated growth due to higher nutrient exposure in preterm infants 
results in an increase in markers of the metabolic syndrome by adolescence
15-19
. 
However, very little is known about drug disposition of low birth offspring in adult life. 
Moreover, the role of nutrition mismatch induced accelerated growth has not been 
examined. 
 
Several clinical and animal studies have observed liver dysfunction in postnatal life of 
low birth weight infants
20-24
. Given that approximately 75% of prescribed drugs are 
metabolized in the liver
25
, liver dysfunction may alter the pharmacokinetic parameters of 
several drugs in postnatal life of these infants. Amongst the prescribed drugs eliminated 
by the liver, three fourths of these are metabolized by the cytochrome P450 (CYP) family 
of enzymes
25
. In humans, reduced intravenous midazolam clearance, a measure of hepatic 
CYP3A4 activity, has been observed in preterm infants aged between 2 to 15 days
26-28
. 
Interestingly, the CYP3A4 isozyme is responsible for the metabolism of approximately 
half of all marketed drugs
29
. Yet, it remains to be investigated whether pharmacokinetics 
of drugs in the liver are altered in adult life of low birth weight offspring.  
 
Animal models make it feasible to investigate alterations in pharmacokinetics of a drug 
due to changes in hepatic CYP enzyme activity. The long-term programming of Cyp3a 
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activity was recently demonstrated by Tajima et. al. in mice offspring born of mothers 
receiving a high fat diet during pregnancy
30
. Specifically, they correlated a decrease in 
hepatic Cyp3a activity in six week old offspring with reduced triazolam substrate 
clearance
30
. Although an important finding, it remains to be established whether similar 
long-term programming of drug metabolizing CYP enzyme activities occur when in utero 
insults result in low birth weight offspring. In rodent experimental models low birth 
weight offspring that undergo accelerated growth rates due to a postnatal nutrition 
mismatch have been previously associated with hypertension
31
, obesity
32
, 
hypercholesterolemia
33
, insulin resistance
32
 and reduced longevity
34
. Therefore, it would 
be of interest to also determine the adverse consequences of altering the postnatal 
nutrition environment of low birth weight offspring on long-term programming of hepatic 
drug metabolizing CYP enzymes.  
Since worldwide maternal under-nutrition is a leading source of impaired perinatal 
development, and given amino acids play a critical role in fetal growth
35
, the maternal 
protein restriction (MPR) dietary regime is a relevant animal model to study the 
developmental origins of adult diseases (DOHaD). In addition, MPR shares features 
common with placental insufficiency induced intrauterine growth restriction (PI-IUGR), 
which occurs in 8% of pregnancies and produces protein deficiency in the developing 
fetus
36-38
. We and others have previously demonstrated that maternal protein restriction 
(MPR, 8% protein) during pregnancy and lactation results in low birth weight offspring 
(asymmetrical IUGR
 39
), which display impaired liver function in adulthood
21-23, 40
. In 
addition, we have observed that these offspring display high circulating and hepatic 
cholesterol levels exclusively when they are faced with a nutritional mismatch of a 
normal (20%) protein diet post-weaning. This was attributed to the long-term repression 
of a hepatic cytochrome P450 enzyme, cholesterol 7α-hydroxylase (Cyp7a1), which is 
rate-limiting for the catabolism of cholesterol to bile acids
41
. It is noteworthy that 
decreased Cyp7a1 expression is also associated with Endoplasmic Reticulum (ER) stress 
in a rat model of hypothyroidism
42
. This is of great interest considering that we have 
recently demonstrated that these MPR offspring have elevated ER stress markers in their 
livers at four months of age
42
. In contrast, MPR derived offspring that were maintained 
on a low protein diet throughout life did not display hypercholesterolemia or hepatic ER 
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stress. As Cyp enzymes (i.e. Cyp3a1, Cyp3a2, Cyp2c11 and Cyp2b1) reside in the ER of 
the liver and are the primary enzymes involved with Phase 1 of drug metabolism
43
, we 
tested the hypothesis that MPR derived low birth offspring may have an impaired activity 
of drug-metabolizing Cyp enzymes in adulthood when faced with a nutritional mismatch 
in postnatal life. To address this, the effects of a low protein diet throughout life (LP1) or 
until the end of lactation (LP2) were compared relative to a normal protein diet 
throughout life of the offspring (C). 
5.2 Materials and Methods 
5.2.1 Animals and Dietary Regimes 
All procedures were performed in accordance with the guidelines set by the Canadian 
Council of Animal Care and upon approval of the Animal Care Committee of the 
University of Western Ontario. Female and male Wistar rats at breeding age (250 g) were 
purchased from Charles River (La Salle, St.Constant, Quebec, Canada). These rats were 
housed in individual cages and maintained at room temperature on a 12-h light, 12-h dark 
cycle. For 3 weeks, these rats were left to acclimatize to the animal care facility and their 
reproductive cycles were followed. At the onset of proestrus, these rats were mated. 
Impregnation was confirmed by the presence of sperm in the vaginal smear the next 
morning. Upon confirmation of impregnation (gestation day 1), the rats were fed either a 
control diet containing 20% protein (Bio-Serv, Frenchtown, NJ, USA, Product# F4576 – 
Rodent Diet, AIN-93G, Blue, ½” pellets) or a LP diet containing 8% protein (Bio-Serv, 
Frenchtown, NJ, USA, Product#F4575 – Rodent Diet, AIN-93G, ½” pellets). The LP diet 
contained similar fat content and was made isocaloric by the addition of carbohydrates 
(Bio-Serv, Frenchtown, NJ, USA). At birth, the litter size was reduced to eight animals 
(four females and four males), with weights closest to the litter mean. This ensured a 
standard litter size for all mothers. Three different dietary regimes were administered to 
these offspring. Offspring derived from a maternal LP diet were either administered the 
LP diet throughout postnatal life (LP1) or until the end of weaning (LP2). Food and water 
was provided ad libitum, and food intake was recorded during pregnancy and in the 
offspring. At embryonic day 19 (e19), a subset of pregnant rats were sacrificed and the 
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fetal livers were excised and snap frozen for quantitative RT-PCR. Another subset of rats 
was allowed to deliver spontaneously. The food intake of these offspring were monitored 
by measuring their food consumption every third day, and have been previously 
published
41
. At postnatal day 130 (d130), the pups were also sacrificed and the medial 
lobe liver tissue was excised and frozen for quantitative RT-PCR and for testosterone 
enzyme kinetics in liver microsomes via ultra performance liquid chromatography. We 
did not examine the female offspring to prevent confounding factors related to their 
estrous cycle and their hormonal profile. Moreover, the maternal low protein model has 
been demonstrated to exhibit early life programming effects in a sexually dimorphic 
manner, which was not the focus of this study
41, 44, 45
. 
5.2.2 Real Time PCR Analysis 
Total RNA from Wistar rat medial lobe liver tissue was extracted at e19 and d130 by the 
one-step method of Chomczynski and Sacchi
46
 (TRIzol, Invitrogen, Carlsbad, CA, USA). 
RNA was treated with deoxyribonuclease to remove any contaminating DNA. 4 µg of the 
total RNA was reverse transcribed to cDNA using random primers and Superscript II 
RNase H-reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Primer sets directed 
against rat Cyp2b1, Cyp3a1, Cyp3a2, Cyp2c11, Car, Pxr, and β-actin were generated via 
Primer Express software (PE Applied Biosystems, Boston, MA, USA) based on 
published sequences (Table 5.1). The relative abundance of each transcript was 
determined by real-time quantitative PCR as previously published
47
. For the quantitative 
analysis of mRNA expression, the Bio-Rad CFX384 Real Time System was employed 
using the DNA binding dye IQ
TM
 SYBR green supermix (Bio-Rad, Mississauga, Ontario, 
Canada). The cycling conditions were 50 C for 2 min, 95 C for 10 min, followed by 45 
cycles of 95 C for 15 sec and 60 C for 1 min. The cycle threshold was set at a level where 
the exponential increase in PCR amplification was approximately parallel between all 
samples. All primer sets produced amplicons of the expected size and sequence. We 
calculated the relative fold changes using the comparative cycle times (Ct) method with 
β-actin as the reference guide. Over a wide range of known cDNA concentrations, all 
primer sets were demonstrated to have good linear correlation (slope=-3.4) and equal 
priming efficiency for the different dilutions compared with their Ct values (data not 
129 
 
 
shown). Given that all primer sets had equal priming efficiency, the ∆Ct values (primer 
internal control) for each primer set were calibrated to the experimental samples with the 
lowest transcript abundance (highest Ct value), and the relative abundance of each primer 
set compared with calibrator was determined by the formula, 2
∆∆Ct, in which ∆∆Ct is the 
calibrated Ct value. 
5.2.3 Hepatic Microsome Isolation 
Wistar rat liver microsomes were isolated by differential centrifugation using methods 
described previously by Velenosi et al.
48
. Briefly, 0.9% NaCl solution was used to rinse 
liver tissue. The rinsed tissue was homogenized in 1.15% KCl solution containing 1 mM 
EDTA and was centrifuged at 9000g for 20 min at 4°C. The subsequent supernatant was 
centrifuged at 105, 000g for 60 min at 4°C. The microsomal pellet was resuspended in 
100 mM potassium phosphate buffer containing 20% glycerol at pH 7.4 and protein 
concentration was determined by colorimetric BCA Protein Assay (Pierce Corp., 
Madison, WI, USA). Microsomal protein extract was stored at -80°C for further analysis. 
5.2.4 Hepatic Metabolism of Testosterone by Cyp3a, Cyp2b and 
Cyp2c Enzymes 
Metabolic activity of Cyp3a and Cyp2c in hepatic microsomes was determined using 
methods previously described by Velenosi et al. (2012)
48
. Testosterone was selected as a 
probe for Cyp3a, Cyp2b and Cyp2c enzyme activity based on previously documented 
selective metabolism by specific rat P450 isozymes
48, 49
. 50 mM potassium phosphate 
buffer and 2 mM MgCl2 (pH 7.4) with 1 mg/ml hepatic microsomal protein equating to a 
final volume of 250l was used for timed enzymatic reactions. Linear rate of production 
of metabolites was determined by varying time, protein and relevant substrate 
concentrations prior to conducting enzymatic reactions. Formation of testosterone 
metabolites (2–OH testosterone, 6-OH testosterone and 16-OH testosterone) was 
determined to be linear at 10 minutes. The reactions were initiated by addition of 1mM 
NADPH to microsomal samples containing varying concentrations of testosterone. The 
reaction was terminated by addition of 50 l of ice-cold acetonitrile followed by 15-
minute incubation on ice and centrifugation to pellet precipitated protein
48
. 
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5.2.5 Testosterone Metabolite Analysis by Ultraperformance 
Liquid Chromatography with Photodiode Array (UPLC-PDA) 
Detection 
Testosterone metabolite analysis was performed by solid-phase extraction followed by 
UPLC-PDA using methods previously described
48
. The solid-phase extraction cartridge 
(C18, Strata-X Polymeric Reverse Phase 33 m; Phenomenex, Torrance, CA) was 
conditioned according to manufacturer’s specification. Carbamazepine was used as an 
internal standard for testosterone quantification. The analytes and internal standard were 
passed across the packing of the cartridge by gravity. The cartridges were then washed 
with 1 ml of Milli-Q water followed by 1 ml of 50:50 methanol/water. 1 ml of methanol 
containing 0.1% triethylamine and 0.1% trifluoroacetic acid was used to elute the 
analytes into clean glass test tubes. The eluent was dried, reconstituted in mobile phase 
and injected on a Phenomenex Kinetex C18 column (1.7 m particle size, 50 x 2.1 mm; 
Torrence, CA) for testosterone and analyte separation. The column was maintained at 
40°C in a Waters ACQUITY UPLC H-Class System. Mobile phase flow, gradient used 
and detection wavelengths were the same as previously published
48
. 
5.2.6 Statistics 
All results were expressed as the mean of arbitrary values  the standard error of the 
mean (SEM). The significance of differences (p<0.05) between mean values were 
evaluated using the unpaired Student’s t-test for ChIP and testosterone enzyme kinetics in 
liver microsomes via ultra performance liquid chromatography. One-way analysis of 
variance (ANOVA) followed by a Bonferroni’s Multiple Comparison post hoc test, was 
used to evaluate significance of differences for results comparing the effect of all the 
dietary regimes for qRT-PCR analysis. 
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Table 5.1. Real Time PCR Primers 
Gene Primer (5’-3’) Reference No. 
Cyp3a1 FWD ACC AGT GGA AGA CTC AAG GAG ATG T XM 003751127 
REV TCA CAG GGA CAG GTT TGC CTT TCT XM 003751127 
Cy3a2 FWD GCT CTT GAT GCA TGG TTA AAG ATT TG  BC 089765 
REV ATC CAC AGA CCT TGC CAA CTC CTT  BC 089765 
Cy2c11 FWD CCC TGA GGA CTT TTG GGA TGG GC  BC 088146 
REV GGG GCA CCT TTG CTC TTC CTC  BC 088146 
Cy2b1 FWD GCT CAA GTA CCC CCA TGT CG XM 003750353 
REV ATC AGT GTA TGG CAT TTT ACT GCG G XM 003750353 
Car FWD CCT TTT CCG TTC CCT GAC CA AB 204900 
REV AGG CAG AAC GTA GTG TTG AGT AB 204900 
Pxr FWD TGC ACA CAG GTT CCT GTT CCT GA AF 151377 
REV GGG GTG CGT GTC CTG GAT GC AF 151377 
β-actin FWD ACG AGG CCC AGA GCA AGA NM 031144 
REV TTG GTT ACA ATG CCG TGT TCA NM 031144 
 
132 
 
 
5.3 Results 
5.3.1 A switch to a normal protein diet in postnatal life of MPR 
derived low birth weight offspring leads to increases in 
hepatic Cyp3a1, Cyp2c11 and Cyp2b1 mRNA expression at 
postnatal day 130 
In this study, we wanted to investigate the long-term effects of MPR derived low birth 
weight offspring on expression and function of major drug metabolizing cytochrome 
P450 (CYP) enzymes in the liver. Q-RT-PCR analysis was conducted to examine the 
steady-state mRNA expression of hepatic Cyp3a1, Cyp3a2, Cyp2c11 and Cyp2b1 at 
postnatal day 130. A 1.79, 1.45 and 1.94 fold increase in Cyp3a1, Cyp2c11, Cyp2b1 
respectively was observed in the livers of MPR offspring who were placed on a normal 
protein diet post-weaning (LP2) compared to the Control (Figure 5.1A, C, D). 
Interestingly, in MPR offspring subjected to protein restriction throughout pregnancy and 
postnatal life (LP1), there was no difference in hepatic Cyp3a1, Cyp3a2, Cyp2c11 and 
Cyp2b1 mRNA expression (Figure 1A, B, C, D). Upon comparing the two MPR dietary 
regimes, the LP2 offspring displayed a 1.93, 1.27 and 3.04 fold elevation in hepatic 
Cyp3a1, Cyp2c11 and Cyp2b1 mRNA expression, respectively, relative to LP1 (Figure 
1A, C, D). There was also a noticeable trend towards an increase in Cyp3a2 mRNA 
expression in LP2 offspring compared to Control and LP1 offspring (P<0.06) (Figure 
5.11B). 
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.  
Figure 5.1: Quantitative RT-PCR mRNA level analysis of A. Cyp3a1, B. Cyp3a2, C. 
Cyp2c11, D. Cyp2b1 in the livers of rat offspring derived at postnatal d 130. RNA was 
extracted and reverse transcribed for quantitative RT-PCR. mRNA level expression was 
assessed via Q-RT-PCR using primers specific for Cyp3a1, Cyp3a2, Cyp2c11, and -
actin. The relative levels of each mRNA transcript were normalized to that of the levels 
of each -actin mRNA transcript. Results were expressed as the mean ± SEM. * Control 
vs LP2 Significant difference (P < 0.05), # LP1 vs LP2 Significant difference (P < 0.05); 
n = 7–8/group, where each n represents an offspring derived from a different mother. 
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5.3.2 Elevated Cyp3a1, Cyp2c11 and Cyp2b1 mRNA levels 
correlated with increases in their drug metabolizing activity 
To evaluate whether postnatal nutritional mismatch in MPR derived low birth weight 
offspring also impacted long-term function of hepatic Cyp3a, Cyp2c and Cyp2b enzyme 
activities, testosterone metabolism assay was performed using rat liver microsomes. This 
assay is an excellent indicator of Cyp3a, Cyp2c and Cyp2b enzyme activity, as 
testosterone metabolites 2OH-testosterone, 16OH-testosterone and 6OH-testosterone 
have been previously observed to be generated by Cyp2c, Cyp2b and Cyp3a enzymes, 
respectively
48, 48
. Full enzyme kinetics of these metabolites was determined for this study. 
Vmax/Km, a measure of intrinsic clearance for 2OH-testosterone, 16OH-testosterone 
and 6OH-testosterone, was significantly elevated by 2.0, 1.9 and 3.25 fold respectively 
in LP2 offspring at postnatal day 130 (Figure 5.2 A, B, C). The increases in intrinsic 
clearance of testosterone metabolites corresponded well with increases in Cyp2c11, 
Cyp2b1 and Cyp3a1 mRNA expression, respectively (Figure 5.1D, C, A). The Michaelis-
Menten kinetic parameters for 2OH-testosterone, 16OH-testosterone and 6OH-
testosterone are presented in Table 5.2. 
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Figure 5.2: Michaelis-Menten plots of A. 2OH-testosterone, B. 16OH-testosterone 
and C. 6OH-testosterone after incubation of rat liver microsomes with 1mM NADPH 
and various concentrations of testosterone. Liver microsomes were extracted and timed 
enzyme reaction was performed for testostereone metabolite analysis via solid-phase 
extraction followed by UPLC-PDA. Each data point on the curves were expressed as the 
mean ± SEM.; n = 5–6/group, where each n represents an offspring derived from a 
different mother. 
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Table 5.2. Michaelis-Menten kinetic values for P450 probe substrates in Control 
and LP2 offspring rat liver microsomes at postnatal d 130 
2α -OH Testosterone 
 
K
m
  
(µM) 
V
max 
(pmol/min/mg protein) 
V
max/Km 
(µl/min/mg protein) 
Control 86 ± 19 500 ± 34 7.12 ± 1.17 
LP2 50 ± 9 615 ± 38* 14.22 ± 2.48* 
6β -OH Testosterone 
 
K
m
  
(µM) 
V
max 
(pmol/min/mg protein) 
V
max/Km 
(µl/min/mg protein) 
Control 172 ± 18 182 ± 27 0.97 ± 0.16 
LP2 123 ± 19 214 ± 21 1.85 ± 0.22** 
16α -OH Testosterone 
 
K
m
  
(µM) 
V
max 
(pmol/min/mg protein) 
V
max/Km 
(µl/min/mg protein) 
Control 80 ± 12 665 ± 58 8 ± 2 
LP2 43 ± 8* 873 ± 83 26 ± 6* 
Data are presented as means ± SEM. 
*P < 0.05 compared with control. 
**P < 0.001 compared with control. 
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5.3.3 Elevated Cyp3a1, Cyp2c11 and Cyp2b1 expression and 
function coincided with increases in constitutive androstane 
receptor (Car) 
We next evaluated whether the elevated activity and steady-state mRNA levels of 
Cyp3a1, Cyp2c11, Cyp2b1 coincided with upregulation of the orphan nuclear receptors 
Car and Pxr. These nuclear receptors serve as master transcription factors which regulate 
the transcription of several xenobiotic detoxification enzymes
50
. As depicted in Figure 
5.3, administering a normal protein diet post-weaning to maternal low protein diet 
derived low birth weight offspring (LP2) resulted in significantly increased expression of 
hepatic Car mRNA levels compared to control in adulthood. This increase was prevented 
in IUGR offspring maintained on a low protein diet throughout fetal and postnatal life 
(LP1). 
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Figure 5.3: Quantitative RT-PCR mRNA level analysis of A. Pxr and B. Car in the livers 
of rat offspring derived at postnatal d 130. RNA was extracted and reverse transcribed for 
quantitative RT-PCR. mRNA level expression was assessed via Q-RT-PCR using 
primers specific for Pxr, Car and -actin. The relative levels of each mRNA transcript 
were normalized to that of the levels of each -actin mRNA transcript. Results were 
expressed as the mean ± SEM. *, Significant difference (P < 0.05); n = 7–8/group, where 
each n represents an offspring derived from a different mother. 
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5.3.4 Major hepatic drug metabolizing Cyp enzymes were 
unaltered by MPR at postnatal day 21.  
Since an increase in Cyp3a, Cyp2b and Cyp2c11 expression and activity was observed by 
adulthood in MPR offspring that received a control protein diet post-weaning (LP2), we 
further pursued whether this increase was exclusively due to a switch in diet post-
weaning or was persistent before the normal protein was restored at postnatal day 21. 
Interestingly, MPR offspring displayed no significant difference in Cyp3a1, Cyp3a2, 
Cyp2b1 and Cyp2c11 mRNA levels compared to control at postnatal day 21 (Figure 5.4). 
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Figure 5.4: Quantitative RT-PCR mRNA level analysis of A. Cyp3a1, B. Cyp3a2, C. 
Cyp2c11, D. Cyp2b1 in the livers of rat offspring derived at postnatal d 21. RNA was 
extracted and reverse transcribed for quantitative RT-PCR. mRNA level expression was 
assessed via Q-RT-PCR using primers specific for Cyp3a1, Cyp3a2, Cyp2c11, and -
actin. The relative levels of each mRNA transcript were normalized to that of the levels 
of each -actin mRNA transcript. Results were expressed as the mean ± SEM. * Control 
vs LP2 Significant difference (P < 0.05), # LP1 vs LP2 Significant difference (P < 0.05); 
n = 7–8/group, where each n represents an offspring derived from a different mother. 
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5.4 Discussion 
In this study we present the novel finding that MPR derived low birth weight rat 
offspring have elevated Cyp3a, Cyp2b and Cyp2c activity in adulthood, exclusively when 
faced with a nutritional mismatch in postnatal life. This was found to coincide with 
increases in their steady-state mRNA levels, which may be due, in part, to transcriptional 
induction by constitutive androstane receptor (Car). Interestingly, when low birth weight 
offspring were maintained on a low protein diet post-lactation, they exhibited no 
differences in expression of these Cyp enzymes. Collectively, this study suggests that 
IUGR offspring receiving an inappropriate dietary intervention strategy may require an 
adjustment to their drug dosages to effectively ameliorate the symptoms of the metabolic 
syndrome. It is conceivable that adopting personalized drug treatment strategies in 
postnatal life of low birth weight offspring may prove to be an effective therapeutic 
approach.  
 
Contrary to our initial hypothesis, administering a normal protein diet post-weaning to 
maternal low protein diet derived low birth weight offspring (LP2) resulted in elevated 
expression of drug metabolizing enzymes Cyp3a1 and Cyp2c11 in adulthood. The LP2 
offspring displayed corresponding increases in intrinsic enzymatic activity of these Cyp 
enzymes. Given that testosterone is also a substrate for these Cyp enzymes, it is 
noteworthy that circulating testosterone has been previously reported to be decreased in 
these LP2 offspring
44
.  Our data now provide evidence for the mechanism underlying this 
observation. Conversely, no differences in the steady-state mRNA expression of these 
Cyp enzymes were observed when the IUGR offspring were maintained on a low protein 
diet (LP1). Moreover, no changes in expression of these Cyp enzymes were observed at 
postnatal day 21, which represents the end of lactation, a time point where normal protein 
was restored for LP2 offspring. This suggests that the postnatal nutritional mismatch is 
likely the more significant contributing factor to elevated Cyp3a1 and Cyp2c11 
expression in adult life, as opposed to the direct actions of the low protein diet itself 
during pregnancy and lactation. Since, increases in Cyp3a and Cyp2c activity correlated 
with Cyp3a1 and Cyp2c11 steady-state mRNA expression in LP2 offspring, we 
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postulated transcriptional mechanisms to underlie the increases in activity. Specifically, 
we attempted to investigate the role of xenobiotic sensing nuclear receptors Pxr and Car 
which represent major transcription factors involved with the transcriptional induction of 
drug-metabolizing Cyp enzymes in humans
51
. In this study we observed an exclusive 
elevation of Car mRNA levels in LP2 offspring. Interestingly, IUGR offspring 
maintained on a low protein diet throughout fetal and postnatal life (LP1) displayed no 
change in the xenobiotic sensing nuclear receptors Pxr and Car. Since, Car binding sites 
have not been well characterized towards explaining the transcriptional induction of 
Cyp3a1, Cyp3a2 and Cyp2c11 genes in rats, we evaluated whether increases in Car 
correlated with the well characterized increases in Cyp2b1 expression
41, 44, 45, 52-54
. As 
anticipated, there was a noticeable increase in both hepatic Cyp2b1 mRNA and activity 
levels in the LP2 adult offspring. Therefore, we propose that the increases in hepatic Car 
expression also underlie the elevated expression and activity of Cyp3a1 and Cyp2c11 in 
these offspring.  
 
In support of the main tenet of the “predictive adaptive response” hypothesis, MPR 
derived low birth weight rat offspring when faced with a nutritional mismatch, have been 
previously reported to display high cholesterol, visceral obesity, hypertension, type 2 
diabetes and reduced longevity
55
. Conversely, in the absence of protein restoration, rat 
IUGR offspring have been observed to live longer
42
. Given that the liver plays a key role 
in metabolism, any alterations in its function can lead to the development of the 
metabolic syndrome and reduced lifespan. We recently observed elevated hepatic ER 
stress exclusively in MPR derived IUGR offspring, which received a nutritional 
mismatch in postnatal life
56
. Interestingly, an elegant study by Pascual et. al. in 2008 
demonstrated that tunicamycin-induced ER stress in HepG2 cells induced the expression 
of CYP2B6, the human ortholog of Cyp2b1
42
. The molecular mechanism behind this 
induction was attributed to ER stress activation of liver enriched activating transcription 
factor 5 (ATF5), which shares close sequence homology to the more ubiquitously 
expressed ATF4. ATF4 activation is known to occur via its selective translation during a 
period of global protein translation attenuation due to elevated phosphorylation of 
eukaryotic initiation factor 2. Therefore, it is possible that activation of ATF5 due to the 
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previously observed hepatic increases in phosphorylation of eukaryotic initiation factor 
256, may also cause the induction in Cyp2b1 expression observed in the study. 
Interestingly, ATF5 has been observed to interact with C/EBP family of transcription 
factors, as well as synergistically potentiate the actions of nuclear receptor Car, which are 
both established regulators of the CYP2B6 gene
57
. With the use of Alggen PROMO 
software, we have identified multiple putative C/EBP binding sites at the promoter of 
all the Cyp enzymes examined in this study.  Therefore, it is conceivable that under 
conditions of high stress (i.e. ER stress), as exhibited in LP2 low birth weight offspring, 
elevation of these xenobiotic metabolizing enzymes may serve as an adaptive response to 
improve its detoxification capacity. 
 
To date there have been no clinical studies conducted to evaluate the effects of low birth 
weight on the pharmacokinetics of drugs in adulthood. This is particularly relevant to 
drugs that would likely be used to manage the symptoms of the metabolic syndrome that 
are observed in these offspring. For instance, despite strong clinical and animal evidence 
linking IUGR to hepatic dysfunction and elevated cholesterol levels in adult life, there is 
little known about whether statin pharmacokinetic or pharmacodynamic parameters are 
altered. Out of all the statins that target the liver, simvastatin, lovastatin and atorvastatin 
are metabolized primarily through CYP3A4, and fluvastatin is metabolized through 
CYP2C9
57
. Since, the rat orthologs of CYP3A4 (i.e. Cyp3a1 and Cyp3a2) and CYP2C11 
(i.e. Cyp2c11) activity was elevated in adulthood, it is likely that low birth weight 
offspring would metabolize statins in the liver at a faster rate. Our data suggest that low 
birth weight offspring may require augmented doses of statins to maintain efficacy 
towards reducing circulating cholesterol levels, a hypothesis which still remains to be 
tested. Moreover, in order to completely understand the impact of low birth weight on 
alterations in pharmacokinetics of drugs, several additional factors need to be evaluated, 
mainly changes in plasma binding protein levels and drug transporter function. It is also 
important to determine whether different insults leading to low birth weight would 
similarly impact drug pharmacokinetic measures in adult life.  
 
144 
 
 
In summary, this study highlights that low birth weight offspring faced with a nutritional 
mismatch in postnatal life have elevated activity of major hepatic phase I drug 
metabolizing enzymes in adulthood. Moreover, maintaining these low birth weight 
offspring on a low protein diet prevented the increases in expression of these enzymes. It 
is plausible that these offspring sense the nutritional mismatch as an unanticipated insult 
and consequently respond by increasing their detoxification capacity via the activation of 
nuclear receptor Car. In light of this study, careful consideration is recommended for 
optimizing drug dosing to ameliorate symptoms of metabolic syndrome in IUGR 
offspring that display nutritional mismatch induced accelerated growth. 
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6 DISCUSSION AND CONCLUSIONS 
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6.1 Summary and Discussion 
6.1.1 Chapter Three 
The aim of Chapter Three was to elucidate the molecular mechanisms which may lead to 
long-term cholesterol dysregulation of MPR derived low birth weight offspring. Given 
placental insufficiency in humans can produce protein deficiency in the fetus, this 
maternal protein restriction model shares features in common with IUGR, which 
represents 8% of newborns
1-3
. The hypothesis was that IUGR offspring may lead to 
elevated cholesterol levels in adult offspring via repressive changes in histone 
modifications at the Cyp7a1 promoter. As shown in Chapter Three, long-term hepatic 
Cyp7a1 transcriptional repression in IUGR offspring derived from a low protein diet 
during pregnancy and lactation underlies the increases in circulating and hepatic 
cholesterol levels in both sexes at postnatal day 21 and exclusively in the male offspring 
at postnatal day 130. This long-term repression in transcription was concomitant with 
diminished acetylation and enhanced methylation of histone H3 [K9,14], markers of 
chromatin silencing, surrounding the promoter region of Cyp7a1. These epigenetic 
modifications originated in part due to diet-induced decreases in fetal hepatic Jmjd2a 
expression, a histone H3 [K9] demethylase. This chapter provides the first evidence 
highlighting the important role of epigenetic mechanisms (i.e. post-translational histone 
modifications) in predisposing under nutrition derived low birth weight offspring to 
increased risk of hypercholesterolemia. In addition, these findings overturn the dogma 
that fetal programming effects are permanent since restoration of proteins in the maternal 
diet during the neonatal period re-established the expression of Cyp7a1 to prevent 
hypercholesterolemia. This restoration was associated with an increase in LXR 
expression. 
6.1.2 Chapter Four 
The aim of Chapter Four was to determine whether nutritional mismatch in postnatal life 
of low birth weight offspring would lead to elevated hepatic endoplasmic reticulum (ER) 
stress in adulthood. The hypothesis was that MPR derived offspring faced with a 
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nutritional mismatch are at a higher risk of developing metabolic syndrome in adult life 
due to presence of elevated hepatic ER stress. As shown in Chapter Four, exclusively 
when MPR derived low birth weight offspring received a “nutritional mismatch” 
postpartum, did they display elevated hepatic ER stress markers, including an increase in 
X box binding protein 1 mRNA splicing levels and elevated ER chaperones (Glucose 
regulated protein 78 and 94) at postnatal day 130. This was concomitant with attenuated 
protein synthesis, as indicated by increased phosphorylation of eukaryotic initiation 
factor 2 alpha at Serine 51 residue. Interestingly, maintaining the low birth weight 
offspring on a low protein diet throughout life prevented hepatic ER stress. These 
findings suggest that in addition to epigenetic and transcriptional mechanisms underlying 
the ‘developmental origins of adult disease’, chronic activation of the ER stress pathway 
may also mediate long-term insulin resistance and hypercholesterolemia. 
6.1.3 Chapter Five 
Given that low birth weight children that undergo accelerated growth display an earlier 
onset of metabolic disease symptoms and are more likely to be prescribed medication to 
manage their symptoms (e.g. statins for hypercholesterolemia), the aim of Chapter Five 
was to investigate whether hepatic drug metabolism is altered in adult life of low birth 
weight offspring. In addition, it was of interest to determine whether this association is 
positively correlated in low birth offspring that display accelerated growth when faced 
with a nutritional mismatch postpartum. The hypotheses was that MPR derived low birth 
weight offspring may have an impaired ability to metabolize drugs in adulthood. As 
shown in Chapter Five, a low protein diet during pregnancy and lactation leads to 
increases in Cyp3a, Cyp2b and Cyp2c enzymatic activity (Vmax/Km) at postnatal day 130. 
This was attributed primarily due to increases in mRNA levels of Cyp3a1, Cyp2b1 and 
Cyp2c11. These elevated mRNA levels originate in part due to induction in expression of 
constitute androstane receptor, which is known to activate gene transcription of these Cyp 
enzymes. Interestingly, low birth weight offspring that were maintained on low protein 
diet postpartum did not display any alterations in Cyp enzyme expression. Collectively, 
these findings suggest that a low birth weight offspring when faced with a nutritional 
mismatch postpartum may require greater doses of drugs, which are metabolized by 
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Cyp3a, Cyp2b and Cyp2c enzymes, in order to exert their therapeutic effects. This is an 
important finding as it is applicable to those individuals who are more likely to be 
prescribed medication (e.g. statins for hypercholesterolemia) for the management of the 
symptoms associated with the metabolic syndrome.  
6.2 Future Directions 
Chapter Three and Four of the thesis provide a mechanistic insight which improves our 
understanding of why low birth weight babies are predisposed to increased risk of 
metabolic syndrome. In identifying some of the underlying mechanisms, this thesis helps 
identify early life dietary and/or drug intervention strategies which can be potentially 
used to lower cholesterol and reduce the incidence of the metabolic syndrome. Such 
strategies could reduce the long-term use of cholesterol lowering drugs in adulthood. 
Moreover, considering that adults that were born low birth weight have a higher 
likelihood of prescribing these drugs, chapter Five emphasizes the importance of 
personalized pharmacological therapy in these individuals. However, upon collectively 
analyzing the findings from the thesis, it is critical to realize that there are a number of 
important questions that still need to be addressed. The following sections of the thesis 
aim to highlight some of these important questions. 
6.2.1 Molecular Mechanisms Underlying Sex-Specific Effects 
observed in Adult Life of Low Birth Weight Offspring 
These studies have demonstrated that elevated circulating cholesterol levels in LP2 
offspring are associated with impaired Cyp7a1 expression in both sexes at three weeks 
(pre-weaning) and exclusively in the males at four months of age
4
. This sex-specific 
effect is consistent with findings from other animal model studies. For example, LP2 
offspring exhibit insulin resistance
5
 and visceral obesity
6
 exclusively in the adult male 
offspring at postnatal day 130. While the mechanisms underlying these sex-specific 
programming effects have not been elucidated, it has been hypothesized that sex steroids 
(i.e. estrogen) protect the female from the development of these disease processes, 
including elevated blood pressure
7
. Evidence for this comes from the Aromatase 
Knockout (ArKO) mouse, which cannot synthesize endogenous estrogens due to 
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disruption of the Cyp19 gene
8
. ArKO females challenged with a high cholesterol diet 
have higher circulating cholesterol levels and lower Cyp7a1 expression compared to 
wild-type females and males of either genotype
8
. Moreover, estrogen replacement 
reversed the hepatic steatosis in male ArKO mice
9
. Interestingly, this reversal is only 
possible at lower doses of estrogen which are comparable to physiological levels in the 
female rats as two previous studies have demonstrated a biphasic response of CYP7A1 to 
estrogen levels in rats
10, 11. Lower doses of 17β Estradiol (an endogenous agonist) 
resulted in an induction of CYP7A1 expression, while at higher doses there was a 
repression of CYP7A1 expression. The molecular mechanism mediating this biphasic 
dose response has not been fully elucidated yet. The effects of estrogen may only be part 
of the reason for the sexual dimorphism, as a loss of circulating testosterone has been 
previously observed in MPR males
5
. It is plausible that the loss of this androgen also 
underlies male-specific impairment of Cyp7a1 and cholesterol catabolism. Elevated 
activity of testosterone metabolizing Cyp3a, Cyp2b and Cyp2c enzymes observed in 
adult life of MPR derived male offspring (Chapter 5) now provide evidence for the 
mechanism underlying this observation. However, to pinpoint the role of these Cyp 
enzymes in male specific decreases in circulating testosterone, their expression in MPR 
females would need to be evaluated. In order to fully elucidate whether estrogen or 
testosterone are protective towards preventing high cholesterol observed in MPR derived 
adult male offspring, one can design in vivo experiments which involve castration of 
MPR derived male offspring followed by a timely supplementation of estrogen or 
testosterone. In conjunction, supplementing estrogen or testosterone in ovariectomized 
MPR derived female offspring would also be considered to conclusively determine the 
role of each hormone in the MPR derived male-specific impairment of cholesterol 
homeostasis. It is also important to account for the role of other hormones in this 
impairment. For instance, MPR male offspring at 130 days of age have two-fold higher 
levels of circulating insulin
5
, which has been known to inhibit Cyp7a1 transcription in 
both rat hepatocytes and streptozotocin (STZ)-induced diabetic rats via decreases in the 
binding of transcription factors Fox01 and Smad3 to the promoter of Cyp7a1
12
. Lastly, 
studies have now demonstrated that sex steroid hormones can influence epigenetic 
mechanisms, including post-translational histone modifications
13
. Therefore, future 
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studies should evaluate whether alterations in the “histone code” due to endocrine 
disruptions mediate these sex-specific effects. Conversely, the impact of the “histone 
code” should also be examined in mediating these endocrine disruptions in low birth 
weight offspring.  
6.2.2 Role of Histone Modifying Enzymes in Initiating and 
Maintaining Transcription of Genes Regulating Cholesterol 
Homeostasis in Low Birth Weight Offspring 
An imbalance of histone modifying enzymes can result in aberrant histone modification 
levels in several disease processes. Consequently, these enzymes have gained a lot of 
attention as potential therapeutic targets over the past decade
14
. Yet, no animal study has 
attempted to examine changes to the global expression profiles of all known histone 
modifying enzymes in placental insufficiency (PI) induced-IUGR. Two studies have 
descriptively investigated changes to in vivo binding of a few histone modifying enzymes 
in order to understand the post-translational histone modifications occurring at the 
promoter region of pdx-1 in pancreatic -cells and glut-4 in skeletal muscles, which 
underlie the development of type 2 diabetes in IUGR rat offspring
15, 16
. However, the role 
of histone modifying enzymes in linking PI-IUGR to other risk factors of the metabolic 
syndrome remains unexplored. The two main natural consequences of placental 
insufficiency are low oxygen and nutrient delivery to the fetus, which can have an effect 
on the expression and activity of histone modifying enzymes. For example, hypoxia has 
been demonstrated to alter the expression and activity of a variety of histone modifying 
enzymes
17-21
. Furthermore, hypoxia has been demonstrated to increase di-methylation of 
Histone H3 K9 mediated by G9a methyltransferase
22
, an enzyme known to be involved 
with bile acid mediated Cyp7a1 repression
23
. As MPR has been well documented to 
result in placental insufficiency with low oxygen and nutrient deliver to the IUGR fetus
24-
28
, a change in expression and activity of a wide variety of histone modifying enzymes 
during development would be expected in this model. Furthermore, given that MPR 
resulted in long-term repression of Cyp7a1, there is a need to examine the changes in 
expression of histone modifying enzymes which result in stable repressive post-
translational histone modifications. Thus far, the steady-state mRNA levels of those [K9] 
demethylases (Jmjd2a, Jmjd2b, Jmjd2c, Jmjd2d) that remove three methyl groups from 
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[K9] of Histone H3 has been examined
29
. Q-RT-PCR revealed that a decrease in the 
hepatic Jmjd2a mRNA was observed at e19 (data not shown). Furthermore, expression of 
histone modifying enzymes needs to be correlated with their in vivo binding changes at 
the promoter of Cyp7a1 with the use of ChIP. This would provide insight into their role 
in establishing and maintaining the chromatin environment at Cyp7a1 promoter region 
and in regulating long-term Cyp7a1 transcription. This role can be further strengthened 
by performing in vitro studies by determining whether Cyp7a1 expression is altered due 
to siRNA knockdown of the candidate histone modifying enzyme. The long-term goal 
should be to further characterize the function of histone modifying enzymes in altering 
long-term transcription of a wide variety of other cholesterol regulatory genes involved 
with catabolism (Cyp8b1)
30
, efflux (ATP binding Cassette Transporters A1, G5 and 
G8)
31
 and synthesis (Srebp-2)
31
 or uptake (LDL Receptor)
31
. This would lead to the 
identification of key histone modifying enzymes that are more specific in prevention of 
hypercholesterolemia. Additionally, it will be the first time research would be geared 
towards investigating how a particular histone modifying enzyme plays a role in 
influencing epigenetic mechanisms governing cholesterol regulation in general. A similar 
approach can be implemented to investigate the role of histone modifying enzymes on 
genes involved with glucose homeostasis. Moreover, the mRNA, protein and ChIP 
library established from these experiments can be used for collaborative projects involved 
with the investigation of the role of histone modifying enzymes in long-term 
transcriptional regulation of hepatic genes associated with other disease processes. 
6.2.3 Preventing the Developmental Origins of 
Hypercholesterolemia and Glucose Intolerance 
Hepatic differentiation in mammals begins at an early stage in utero, during which liver 
has a major hematopoietic function until birth
32
. In rodents, the liver bud is formed 
containing bipotential progenitor cells that differentiate into either hepatocytes or ductal 
cells at mid-gestation
32
. In the last three days of gestation, a high rate of fetal hepatocyte 
proliferation results in the tripling of total liver weight
33
. This is followed by a transition 
of fetal to adult rat hepatocytes in the first week of postnatal life
34
. Given that there is a 
high rate of neogenesis, replication and apoptosis during this neonatal period in rats
33
, it 
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represents a critical window for therapy designed to improving hepatic function and 
proliferation. It has been previously demonstrated that the neonatal administration of 
Exendin-4 (a GLP-1 analogy) in IUGR rats derived from uterine-ligated dams rescued β-
cell function and prevented the development of diabetes
35-37
. This was attributed to be 
due to the restoration of expression of a key transcription factor Pdx-1, via epigenetic 
mechanism induced alterations at its promoter region. In addition, Exendin-4 treatment 
during this neonatal period has been demonstrated to prevent the development of hepatic 
oxidative stress and insulin resistance
35
. These studies remarkably illustrate that neonatal 
intervention can influence both pancreatic and liver development long-term. Future 
studies should be aimed at investigating how we can exploit this plasticity in liver 
development to correct the abnormalities that result from an adverse in utero 
environment.  
Attempts were made to correct the hypercholesterolemia in MPR derived IUGR offspring 
by administering an LXR agonist (GW3695) from postnatal day 5 to 15 (Figure 6.1). The 
LXR agonist GW3695 was chosen for these studies in MPR offspring for several reasons: 
(1) restoration of proteins during neonatal life (LP3) stimulated LXR expression and 
restored cholesterol homeostasis, (2) hepatic LXR expression is impaired in MPR 
offspring at day 130
38
, (3) diminished  hepatic LXR in MPR offspring also mediates their 
impaired glucose tolerance
36
 and (4) GW3695 has been previously used in neonatal rat 
studies in vivo to effectively boost LXR activity
39, 40
. Interestingly, a week later (postnatal 
day 21), these offspring had decreased circulating LDL:HDL cholesterol ratios which 
was concomitant with elevated LXR and Cyp7a1 expression41. Furthermore, this was 
associated with a permissive chromatin environment as assessed by increases in the 
acetylation of histone H3 [lysine 9] surrounding the LXRE of the Cyp7a1 promoter
41
. 
Investigations to determine whether these changes are maintained in adulthood as a 
consequence of this neonatal LXR are currently underway. Future studies should also 
focus on determining whether this intervention will reverse the glucose impairment 
observed in these offspring in adult life. 
In Chapter Four it was demonstrated that a mismatched diet leads to increased ER stress 
in IUGR rats. However, little is known about whether early intervention with diet or 
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drugs could alleviate ER stress and symptoms of the metabolic syndrome long-term. In 
adults, a number of studies have demonstrated significant clinical implications of 
therapies to improve metabolic control by alleviating ER stress. In humans, weight loss 
has been associated with a decrease in ER stress markers in the adipose and liver 
tissues
42
. Furthermore, chemical and molecular chaperones have received a lot of 
attention as agents improving metabolic control and insulin sensitivity in animal models, 
as well as in obese humans
43-46
. For instance, the chemical chaperone sodium 4-
phenylbutyrate (PBA), has been demonstrated to reduce ER stress induced by either 
hepatocellular injury or chronic oleate exposure in mice
47, 48
. In humans, oral 
administration of PBA has been observed to alleviate insulin resistance and  cell 
dysfunction
49
. Although PBA is not safe to use during pregnancy, it is routinely used in 
children for the treatment of urea cycle disorders 
(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000219/WC500024753.pdf)
50
. Therefore, despite being 
unsafe during pregnancy, it may prove to be an effective agent for intervention during 
neonatal life of IUGR offspring. Orally active Tauroursodeoxycholic Acid (TUDCA) is 
another example of chemical chaperone that has been demonstrated to improve insulin 
sensitivity of the liver and skeletal muscle in animals and humans
43, 46
. Interestingly, 
unconjugated Ursodeoxycholic acid (UDCA) is clinically approved for the treatment of 
intrahepatic cholestasis during pregnancy
51-53
. In addition, UDCA has been demonstrated 
to reduce apoptosis in human placental explants treated with increasing levels of bile 
acids
54, 55
. However, the use of TUDCA for the purpose of preventing placental 
insufficiency by increasing its ER folding capacity has never been investigated. In 
addition, the use of PBA or TUDCA during neonatal life has not been considered in 
preventing the onset of the metabolic syndrome in IUGR offspring. It is conceivable that 
short-term intervention, which exploits liver plasticity during development, by 
administration of chemical ER chaperones would help prevent the observed increases in 
cholesterol levels and glucose intolerance in the adulthood
4, 56
. Studies with similarity to 
the LXR agonist neonatal intervention approach are currently underway to determine if 
oral administration of TUDCA (1g/Kg body weight) will prevent ER stress and rescue 
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the high cholesterol levels and glucose impairment of MPR derived IUGR offspring in 
adult life (Figure 6.1). 
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Figure 6.1: Neonatal Drug Intervention Studies. Cholesterol and glucose homeostatic 
parameters will be examined in four separate dietary regimes which include a normal 
(20%) protein diet administered a vehicle (Vehicle + CONTROL) or a drug (Drug + 
CONTROL) and a low (8%) protein diet during pregnancy and weaning alongside 
administration of a Vehicle (Vehicle + LP2) or a drug (Drug + LP2) from postnatal day 5 
to 15. Vehicle and drugs were administered intra-peritoneal (IP). Vehicle: DMSO 
(50mg/kg IP). Drug: LXRα Agonist GW3695 (50mg/kg IP) or ER chaperone TUDCA 
(1g/kg administered orally). 
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6.2.4 Investigating Alterations in Drug Metabolism in Adulthood of 
IUGR Offspring 
Based on the findings presented in this thesis, IUGR offspring are more likely to be 
prescribed drugs for management of metabolic risk factors. However, epidemiological 
studies have not been conducted to determine if this is indeed true. In Chapter Five, a 
MPR rat model was used to demonstrate that IUGR offspring have elevated activity of 
important hepatic drug metabolizing Cyp enzymes in adulthood. These findings 
suggested that IUGR offspring would require augmented doses of drugs in adult life in 
order to exert their therapeutic effect when compared to normal birth weight offspring. 
Further experimentation is required in order to validate this point. A quick indicator of 
whether pharmacokinetics of a drug is altered in animals can be derived from the 
zoxazolamine paralysis assay, where a decrease in duration of paralysis is related to faster 
clearance of zoxazolamine
57
. For a more thorough and conclusive analysis, 
pharmacokinetic parameters of drugs of interest need to be correlated with their 
respective drug disposition molecular pathways in adult life of IUGR offspring. These 
pathways mainly include Phase I and Phase II drug metabolizing enzymes, plasma 
binding proteins, uptake proteins and transporters in several tissues. Moreover, it remains 
to be determined whether different insults leading to IUGR would similarly impact drug 
pharmacokinetic measures in adult life. 
6.3 Conclusions 
The impact of adverse events during development on an individual’s long-term wellbeing 
is undoubtedly strong. In most cases these adverse events can be prevented from 
occurring by intervention. However, there are several scenarios where adverse events 
remain unnoticed or have already impacted developmental processes by the time they are 
recognized. Therefore, development of biomarkers, which provide earlier identification 
of impaired development would be invaluable in these situations. However, until this can 
be achieved, it is imperative to increase our understanding of the underlying mechanisms 
which program offspring impacted by these adverse events to an increased risk of adult 
diseases. Therefore, the focus of this thesis was to investigate these mechanisms in order 
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to enhance our understanding of why low birth weight offspring have increased risk of 
developing the metabolic syndrome in adult life (Figure 6.2). In the first section of the 
thesis, elevated cholesterol levels in low birth weight offspring were shown to be linked 
to long-term repressive changes in histone modifications at the promoter of Cholesterol 
7-Hydroxylase, a rate-limiting enzyme involved with cholesterol catabolism. The 
second section of the thesis provided novel evidence to suggest that in addition to 
epigenetic and transcriptional mechanisms underlying the ‘developmental origins of adult 
disease’, activation of hepatic ER stress may mediate long-term insulin resistance and 
hypercholesterolemia observed in these offspring (Figure 6.2). Moreover, these two 
sections provide support to the “Predictive Adaptive Response” hypothesis, as the 
impairment in hepatic cholesterol catabolism and ER stress was present exclusively in the 
IUGR rat offspring which received a nutritional mismatch and displayed accelerated 
growth rates in postnatal life. By understanding the role of these molecular mechanisms 
in mediating these developmental abnormalities, better strategies for preventing the onset 
of adult diseases can be developed. The third section of this thesis focuses on 
investigating mechanisms which will enable the development of strategies for risk 
management as opposed to risk prevention (Figure 6.2). Given that IUGR offspring are 
more likely to be prescribed medication for management of the metabolic syndrome, the 
impact of IUGR on Phase I of drug metabolizing enzymes in adulthood was investigated 
in Chapter Five. The findings demonstrated that IUGR offspring when faced with a 
nutritional mismatch had elevated Cy3a, Cyp2b and Cyp2b enzyme activity, suggesting 
the need for augmented doses of drugs metabolized by these enzymes in order to manage 
the symptoms of the metabolic syndrome in adult life. Overall, it is anticipated that the 
findings presented in this thesis will lead to a better understanding of the molecular 
mechanisms underlying the early programming of the liver.  
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Figure 6.2: Schematic summary of the Thesis 
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